

# Melanoma staging: Evidence-based changes in the American eighth edition cancer staging manual

Ca-A Cancer Journal for Clinicians

67, 472-492

DOI: [10.3322/caac.21409](https://doi.org/10.3322/caac.21409)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Has the melanoma information tsunami become a maelstrom?. <i>Melanoma Management</i> , 2017, 4, 179-182.	0.1	0
3	ECCO essential requirements for quality cancer care: Melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 164-178.	2.0	41
4	Breslow Density Is a Novel Prognostic Feature That Adds Value to Melanoma Staging. <i>American Journal of Surgical Pathology</i> , 2018, 42, 715-725.	2.1	11
6	Adjuvant Therapy in the Treatment of Melanoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1807-1813.	0.7	7
7	Linfadenectomía tras una biopsia positiva del ganglio centinela en el melanoma: un cambio de paradigma. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 298-302.	0.2	6
8	Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 545-549.	0.7	5
9	More on Adjuvant Therapy in Resected Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1656-1657.	13.9	5
10	Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. <i>European Journal of Cancer</i> , 2018, 96, 25-33.	1.3	59
11	Association of Skin Examination Behaviors and Thinner Nodular vs Superficial Spreading Melanoma at Diagnosis. <i>JAMA Dermatology</i> , 2018, 154, 544.	2.0	23
12	Obstacles to improving outcomes in the treatment of uveal melanoma. <i>Cancer</i> , 2018, 124, 2693-2703.	2.0	15
13	<sc>PD</sc>–L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients. <i>Histopathology</i> , 2018, 73, 386-396.	1.6	22
14	T cell–induced CSF1 promotes melanoma resistance to PD1 blockade. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	229
15	Diseción ganglionar en el paciente con melanoma y metástasis en el ganglio centinela: propuesta de decisión basada en la evidencia actual. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 390-398.	0.2	8
16	Cells to Surgery Quiz: February 2018. <i>Journal of Investigative Dermatology</i> , 2018, 138, e21.	0.3	0
17	Emerging Biomarkers in Cutaneous Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 203-218.	1.6	35
18	Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. <i>American Journal of Surgical Pathology</i> , 2018, 42, 359-366.	2.1	11
19	Update on adjuvant melanoma therapy. <i>Current Opinion in Oncology</i> , 2018, 30, 118-124.	1.1	12
20	Follow-Up Recommendations after Diagnosis of Primary Cutaneous Melanoma: A Population-Based Study in New South Wales, Australia. <i>Annals of Surgical Oncology</i> , 2018, 25, 617-625.	0.7	18

#	ARTICLE	IF	CITATIONS
21	Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8mm Separates Higher-Risk and Lower-Risk Tumors. <i>Annals of Surgical Oncology</i> , 2018, 25, 894-902.	0.7	69
22	Management of Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 85-88.	13.9	8
23	Melanoma Surveillance Strategies: Different Approaches to a Shared Goal. <i>Annals of Surgical Oncology</i> , 2018, 25, 583-584.	0.7	6
24	Influence of variability in assessment of Breslow thickness, mitotic rate and ulceration among US pathologists interpreting invasive melanoma, for the purpose of AJCC staging. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 588-596.	0.7	8
25	Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study. <i>Pathology</i> , 2018, 50, 402-410.	0.3	6
26	Melanoma staging: Varying precision and terminal digit clustering in Breslow thickness data is evident in a population-based study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 118-125.e1.	0.6	6
27	Personal history of non-melanoma skin cancer diagnosis and death from melanoma in women. <i>International Journal of Cancer</i> , 2018, 142, 1536-1541.	2.3	3
28	Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: A Dutch population-based study. <i>European Journal of Cancer</i> , 2018, 92, 100-107.	1.3	8
29	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018, 91, 168-170.	1.3	33
30	Moving treatments earlier to move further forwards. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 75-76.	12.5	7
31	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. <i>JCO Precision Oncology</i> , 2018, 2018, 1-19.	1.5	19
32	Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience. <i>Dermatologic Surgery</i> , 2018, 44, 1501-1508.	0.4	10
33	Management of In-Transit Melanoma: We Need Some High-Quality Data. <i>Journal of Oncology Practice</i> , 2018, 14, 302-303.	2.5	1
34	Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?. <i>Journal of Clinical Oncology</i> , 2018, 36, 1649-1653.	0.8	4
35	Primary Cutaneous Melanocytic Neoplasms. , 2018, , 1-28.		0
36	Inflammation: A key process in skin tumorigenesis (Review). <i>Oncology Letters</i> , 2018, 17, 4068-4084.	0.8	77
37	Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 648-651.	0.6	23
38	The Modern Approach to Targeting Melanoma. , 2018, , .		2

#	ARTICLE	IF	CITATIONS
39	The rule of 10s versus the rule of 2s: High complication rates after conventional excision with postoperative margin assessment of specialty site versus trunk and proximal extremity melanomas. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 442-452.	0.6	35
40	Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. <i>The Cochrane Library</i> , 2018, 2018, CD013187.	1.5	10
41	Optical coherence tomography for diagnosing skin cancer in adults. <i>The Cochrane Library</i> , 2018, 12, CD013189.	1.5	59
42	Visual inspection for diagnosing cutaneous melanoma in adults. <i>The Cochrane Library</i> , 2018, 2018, CD013194.	1.5	32
43	Natural history of pain associated with melanoma surgery. <i>Pain Reports</i> , 2018, 3, e689.	1.4	5
44	The dynamics of medical care in skin cancers. <i>Current Opinion in Oncology</i> , 2018, 30, 105-106.	1.1	0
45	High-frequency ultrasound for diagnosing skin cancer in adults. <i>The Cochrane Library</i> , 2018, 2018, CD013188.	1.5	45
46	Teledermatology for diagnosing skin cancer in adults. <i>The Cochrane Library</i> , 2018, 2018, CD013193.	1.5	74
47	ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. <i>Annals of Surgical Oncology</i> , 2018, 25, 918-919.	0.7	1
48	Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1100, 83-95.	0.8	10
49	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 2480.	2.2	57
50	Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy. <i>British Journal of Cancer</i> , 2018, 119, 1339-1346.	2.9	40
51	Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. <i>The Cochrane Library</i> , 2018, 2018, CD011902.	1.5	89
52	The existence of early stage oral mucosal melanoma: A 10-year retrospective analysis of 170 patients in a single institute. <i>Oral Oncology</i> , 2018, 87, 70-76.	0.8	16
53	Wishing to be perceived as a capable and resourceful person – A qualitative study of melanoma patients' experiences of the contact and interaction with healthcare professionals. <i>Journal of Clinical Nursing</i> , 2018, 28, 1223-1232.	1.4	6
54	Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. <i>Lancet Oncology</i> , The, 2018, 19, e720-e725.	5.1	25
55	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	15.2	592
56	A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. <i>Journal of Surgical Oncology</i> , 2018, 118, 922-927.	0.8	11

#	ARTICLE	IF	CITATIONS
57	Subungual melanoma: A retrospective cohort of 157 cases from Brazilian National Cancer Institute. <i>Journal of Surgical Oncology</i> , 2018, 118, 1142-1149.	0.8	16
58	Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 55.	1.3	20
59	Acral Melanoma: A Patient's Experience and Physician's Commentary. <i>Dermatology and Therapy</i> , 2018, 8, 503-507.	1.4	1
60	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. <i>Cancer Treatment Reviews</i> , 2018, 71, 8-18.	3.4	58
61	The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. <i>Current Oncology Reports</i> , 2018, 20, 87.	1.8	119
62	Risk factors for development of new skin neoplasms in patients with past history of skin cancer: A survival analysis. <i>Scientific Reports</i> , 2018, 8, 15744.	1.6	14
64	A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky032.	1.4	23
65	Genetic polymorphisms may influence the vertical growth rate of melanoma. <i>Journal of Cancer</i> , 2018, 9, 3078-3083.	1.2	2
66	Omitting Completion Dissection in Melanoma? Help is Available for Surgeons Coping Without Routine Dissection, But More Work is Needed. <i>Annals of Surgical Oncology</i> , 2018, 25, 3416-3418.	0.7	3
67	The relationship between mitotic rate and depth of invasion in biopsies of malignant melanoma. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2018, Volume 11, 125-130.	0.8	7
68	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC?. <i>British Journal of Dermatology</i> , 2018, 179, 1422-1423.	1.4	7
69	Clinically amelanotic or hypomelanotic melanoma: Anatomic distribution, risk factors, and survival. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 645-651.e4.	0.6	39
70	Melanoma. <i>Lancet</i> , The, 2018, 392, 971-984.	6.3	1,016
71	Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. <i>Journal of Surgical Oncology</i> , 2018, 118, 599-605.	0.8	13
73	Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. <i>Cureus</i> , 2018, 10, e3700.	0.2	25
74	Staging of Cutaneous Melanoma. <i>JAMA Network Open</i> , 2018, 1, e180086.	2.8	4
75	The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors. <i>Contemporary Clinical Trials</i> , 2018, 70, 106-116.	0.8	19
76	1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 2541-2549.	0.7	35

#	ARTICLE	IF	CITATIONS
77	Lymph Node Dissection in Patients With Melanoma and Sentinel Lymph Node Metastasis: An Updated, Evidence-Based Decision Algorithm. <i>Actas Dermo-sifiliogr</i> , 2018, 109, 390-398.	0.2	2
78	Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy in Melanoma: A Paradigm Shift. <i>Actas Dermo-sifiliogr</i> , 2018, 109, 298-302.	0.2	0
79	Cutaneous melanoma in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27292.	0.8	24
80	Targeting tumor-associated acidity in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1331-1348.	2.0	55
81	Essential Components of Melanoma Histopathological Reporting: The Surgical Oncologist's Perspective. <i>Journal of Skin Cancer</i> , 2018, 2018, 1-4.	0.5	5
82	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	0.6	135
83	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. <i>British Journal of Cancer</i> , 2018, 119, 339-346.	2.9	83
84	Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma. <i>Surgery</i> , 2018, 164, 589-593.	1.0	21
85	The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K.. <i>British Journal of Dermatology</i> , 2018, 179, 824-828.	1.4	51
86	Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. <i>Human Molecular Genetics</i> , 2018, 27, 4145-4156.	1.4	34
87	When is surgery for metastatic melanoma still the most appropriate treatment option?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 943-945.	1.1	2
88	Malignant Melanoma: Diagnostic and Management Update. <i>Plastic and Reconstructive Surgery</i> , 2018, 142, 202e-216e.	0.7	45
89	Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1571-1578.	2.0	35
90	Reply to "Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma". <i>Nature Communications</i> , 2018, 9, 2922.	5.8	3
91	Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 639-646.	3.3	1
92	MiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cells. <i>Cancer Management and Research</i> , 2018, Volume 10, 989-1003.	0.9	93
93	Primary Solitary Intracranial Malignant Melanoma: A Systematic Review of Literature. <i>World Neurosurgery</i> , 2018, 117, 386-393.	0.7	19
94	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment: A Review From the Melanoma Perspective and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1474.	2.2	174

#	ARTICLE	IF	CITATIONS
95	Clinical Perspective of 3D Total Body Photography for Early Detection and Screening of Melanoma. <i>Frontiers in Medicine</i> , 2018, 5, 152.	1.2	62
96	Melanoma Immunotherapy: Next-Generation Biomarkers. <i>Frontiers in Oncology</i> , 2018, 8, 178.	1.3	53
97	Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 202.	1.3	35
98	Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. <i>Cancer Cell</i> , 2018, 34, 56-68.e9.	7.7	113
99	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. <i>Annals of Oncology</i> , 2018, 29, 1843-1852.	0.6	47
100	An update on cutaneous melanocytic lesions. <i>Diagnostic Histopathology</i> , 2018, 24, 313-319.	0.2	0
101	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520.	1.7	9
102	Regional therapies for locoregionally advanced and unresectable melanoma. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 495-502.	1.7	12
104	Serum exosomal microRNAs as potent circulating biomarkers for melanoma. <i>Melanoma Research</i> , 2018, 28, 295-303.	0.6	55
105	Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities. <i>Annals of Surgical Oncology</i> , 2018, 25, 3476-3482.	0.7	6
106	National practice patterns of completion lymph node dissection for sentinel nodeâ€­positive melanoma. <i>Journal of Surgical Oncology</i> , 2018, 118, 493-500.	0.8	9
107	Intraoperative Imaging with a Portable Gamma Camera May Reduce the False-Negative Rate for Melanoma Sentinel Lymph Node Surgery. <i>Annals of Surgical Oncology</i> , 2018, 25, 3326-3333.	0.7	19
109	Association between Breslow thickness and dermoscopic findings in acral melanoma. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 831-835.	0.6	22
110	Sentinel lymph node biopsy in cutaneous melanoma of the head and neck using the indocyanine green SPY Elite system. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2018, 39, 485-488.	0.6	14
111	Anthropometric factors and Breslow thickness: prospective data on 2570 cases of cutaneous melanoma in the population-based Janus Cohort. <i>British Journal of Dermatology</i> , 2018, 179, 632-641.	1.4	15
112	Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. <i>Annals of Surgical Oncology</i> , 2018, 25, 2105-2110.	0.7	338
113	Association between Kiâ€­67 expression and clinical outcomes among patients with clinically nodeâ€­negative, thick primary melanoma who underwent nodal staging. <i>Journal of Surgical Oncology</i> , 2018, 118, 150-156.	0.8	7
114	History of Melanoma. , 2018, , 1-13.		1

#	ARTICLE	IF	CITATIONS
115	Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. <i>European Journal of Cancer</i> , 2018, 99, 58-65.	1.3	8
116	It is finally time for adjuvant therapy in melanoma. <i>Cancer Treatment Reviews</i> , 2018, 69, 101-111.	3.4	37
117	An integrated clinical-dermoscopic risk scoring system for the differentiation between early melanoma and atypical nevi: the iDScore. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2162-2170.	1.3	28
118	Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 272-274.	0.6	11
119	Primary Cutaneous Melanocytic Neoplasms. , 2019, , 337-364.		0
120	Melanoma Clinical Staging (Historical and Current). , 2019, , 485-500.		0
121	Evolving Role of the Oncology Nurse in the Care of Patients with Melanoma. , 2019, , 791-817.		0
122	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	1.3	132
123	Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3962-3971.	0.7	5
124	Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. <i>European Journal of Cancer</i> , 2019, 119, 18-29.	1.3	44
125	Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1417-1428.	2.0	23
126	Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). <i>Melanoma Management</i> , 2019, 6, MMT19.	0.1	21
127	New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>Journal of Translational Medicine</i> , 2019, 17, 266.	1.8	27
128	Diagnosing melanoma: the method matters. <i>Medical Journal of Australia</i> , 2019, 211, 209-210.	0.8	1
129	Diagnosis and management of vulvar cancer: A review. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1387-1396.	0.6	45
130	Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma – A combined IHC score for melanoma risk stratification. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 800-808.	0.4	12
132	Update on Current Treatment Recommendations for Primary Cutaneous Melanoma. <i>Dermatologic Clinics</i> , 2019, 37, 397-407.	1.0	13
133	Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. , 2019, 7, 196.		62



#	ARTICLE	IF	CITATIONS
134	Neoadjuvant therapy of locally/regionally advanced melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986695.	1.4	21
135	Surgical cost implications of the AJCC v8 staging system for melanoma and the melanoma in focus consensus statement. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2019, 72, 1700-1738.	0.5	0
136	Surgery for gastrointestinal metastases of malignant melanoma – a retrospective exploratory study. World Journal of Surgical Oncology, 2019, 17, 123.	0.8	8
137	Journey of the Patient With Melanoma: Understanding Resource Use and Bridging the Gap Between Dermatologist, Surgeon, and Oncologist in Different Health Care Systems. Journal of Global Oncology, 2019, 5, 1-8.	0.5	2
138	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 2019, 106, 1319-1326.	0.1	5
139	The “OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers. Seminars in Cancer Biology, 2019, 59, 165-174.	4.3	23
140	Prognostic factors for pulmonary metastasectomy in malignant melanoma: size matters. European Journal of Cardio-thoracic Surgery, 2019, 56, 1104-1109.	0.6	7
141	Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage. World Journal of Surgical Oncology, 2019, 17, 129.	0.8	14
142	Differences between pure desmoplastic melanoma and superficial spreading melanoma in terms of survival, distribution and other clinicopathologic features. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1899-1906.	1.3	12
143	Sex matters: men with melanoma have a worse prognosis than women. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2062-2067.	1.3	28
144	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. , 2019, , 1-28.		0
145	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
146	Correlates of response and outcomes with talimogene laherperpvec. Journal of Surgical Oncology, 2019, 120, 558-564.	0.8	17
147	Current Immunotherapy Practices in Melanoma. Surgical Oncology Clinics of North America, 2019, 28, 403-418.	0.6	18
148	Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. Annals of Surgical Oncology, 2019, 26, 4621-4630.	0.7	10
149	Number of levels required to assess Breslow thickness in cutaneous invasive melanoma: An observational study. Journal of Cutaneous Pathology, 2019, 46, 819-822.	0.7	2
150	An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?. Melanoma Management, 2019, 6, MMT24.	0.1	4
151	A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. Journal of Surgical Oncology, 2019, 120, 1276-1283.	0.8	14

#	ARTICLE	IF	CITATIONS
152	Expression of CMV protein pp65 in cutaneous malignant melanoma. PLoS ONE, 2019, 14, e0223854.	1.1	1
153	Applications of biomarkers for different purposes in drug development. , 2019, , 11-40.		1
154	Analytical discrepancies and their potential impact on biomarkers and precision medicine initiative. , 2019, , 215-239.		0
155	Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. European Journal of Cancer, 2019, 123, 83-91.	1.3	15
156	The Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma. Frontiers in Medicine, 2019, 6, 231.	1.2	11
157	Enzyme responsiveness enhances the specificity and effectiveness of nanoparticles for the treatment of B16F10 melanoma. Journal of Controlled Release, 2019, 316, 208-222.	4.8	19
158	Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma. Expert Review of Clinical Pharmacology, 2019, 12, 1107-1119.	1.3	11
159	Novel Targets for the Treatment of Melanoma. Current Oncology Reports, 2019, 21, 97.	1.8	15
160	Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. The Cochrane Library, 2019, 7, CD012806.	1.5	22
161	Use of circulating tumoral DNA to guide treatment for metastatic melanoma. Pharmacogenomics, 2019, 20, 1259-1270.	0.6	6
163	Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma. International Journal of Biological Markers, 2019, 34, 414-420.	0.7	6
164	The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre. Annals of Surgical Oncology, 2019, 26, 4673-4680.	0.7	6
165	The adjuvant treatment revolution for high-risk melanoma patients. Seminars in Cancer Biology, 2019, 59, 283-289.	4.3	40
168	ASO Author Reflections: Effects of the Updated AJCC Classification for Patients with Stage III Melanoma. Annals of Surgical Oncology, 2019, 26, 713-714.	0.7	0
169	NEAT1/miR-23a-3p/KLF3: a novel regulatory axis in melanoma cancer progression. Cancer Cell International, 2019, 19, 217.	1.8	45
170	Practice Patterns and Prognostic Value of Sentinel Lymph Node Biopsy for Thick Melanoma: A National Cancer Database Study. Annals of Surgical Oncology, 2019, 26, 4651-4662.	0.7	9
171	Oncodermatology of the Head and Neck. Facial Plastic Surgery, 2019, 35, 368-376.	0.5	2
172	Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. Tumori, 2019, 105, 465-473.	0.6	4

#	ARTICLE	IF	CITATIONS
173	Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. <i>Journal of Clinical Oncology</i> , 2019, 37, 3000-3008.	0.8	155
174	Common Nevus and Skin Cutaneous Melanoma: Prognostic Genes Identified by Gene Co-Expression Network Analysis. <i>Genes</i> , 2019, 10, 747.	1.0	17
175	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
176	Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study. <i>Oncology Reports</i> , 2019, 42, 1793-1804.	1.2	13
177	Serological landscape of cytokines in cutaneous melanoma. <i>Cancer Biomarkers</i> , 2019, 26, 333-342.	0.8	4
178	Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8th Edition American Joint Committee on Cancer Staging System?. <i>Journal of the American College of Surgeons</i> , 2019, 228, 466-472.	0.2	31
179	A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 722-726.	0.6	14
180	Coexpression network analysis identified that plakophilin 1 is associated with the metastasis in human melanoma. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 1234-1242.	2.5	18
181	Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study. <i>Cancer Medicine</i> , 2019, 8, 4235-4244.	1.3	42
182	Poliosis Circumscripta: A Mark of Melanoma. <i>American Journal of Medicine</i> , 2019, 132, 1417-1418.	0.6	3
183	Anatomic location of primary melanoma: Survival differences and sun exposure. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 500-509.	0.6	29
184	Development and Initial Validation of Calculated Tumor Area as a Prognostic Tool in Cutaneous Malignant Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 890.	2.0	14
185	ASO Author Reflections: The Impacts of a Negative Sentinel Lymph Node on Quality of Life. <i>Annals of Surgical Oncology</i> , 2019, 26, 651-652.	0.7	1
186	Caveolin-1 and dynamin-2 overexpression is associated with the progression of bladder cancer. <i>Oncology Letters</i> , 2019, 18, 219-226.	0.8	18
187	The prognostic value of the proteasome activator subunit gene family in skin cutaneous melanoma. <i>Journal of Cancer</i> , 2019, 10, 2205-2219.	1.2	25
188	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	5.1	346
189	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971.	5.1	126
190	The course of stage III melanoma in accordance with the severity of node involvement. <i>Current Medical Research and Opinion</i> , 2019, 35, 1819-1824.	0.9	1

#	ARTICLE	IF	CITATIONS
191	Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1187-1194.	2.0	40
192	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	1.3	64
193	A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. <i>Annals of Surgical Oncology</i> , 2019, 26, 2839-2845.	0.7	16
194	Approaches to High-Risk Resected Stage II and III Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e207-e211.	1.8	18
195	Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins. <i>Melanoma Management</i> , 2019, 6, MMT17.	0.1	0
196	An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. <i>Cancer</i> , 2019, 125, 3013-3024.	2.0	14
197	Cells to Surgery Quiz: May 2019. <i>Journal of Investigative Dermatology</i> , 2019, 139, e53-e58.	0.3	0
198	Role of interleukin-24 in the tumor-suppressive effects of interferon- $\gamma$ on melanoma. <i>Experimental Dermatology</i> , 2019, 28, 836-844.	1.4	7
199	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e59-e69.	1.8	8
200	Pathological review of primary cutaneous malignant melanoma by a specialist skin cancer multidisciplinary team improves patient care in the UK. <i>Journal of Clinical Pathology</i> , 2019, 72, 482-486.	1.0	8
201	Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas. <i>British Journal of Dermatology</i> , 2020, 182, 156-165.	1.4	16
202	Treatment of Occupational Skin Cancer. , 2019, , 1-10.		0
204	Cutaneous melanoma in patients from western Mexico: Clinical pathology characteristics and their relationship to prognosis. <i>Australasian Journal of Dermatology</i> , 2019, 60, e298-e303.	0.4	0
205	Negative Sentinel Lymph Node Biopsy in Patients with Melanoma: The Patient's Perspective. <i>Annals of Surgical Oncology</i> , 2019, 26, 2263-2267.	0.7	11
206	Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor. <i>JAMA Dermatology</i> , 2019, 155, 688.	2.0	74
207	Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. <i>Journal of Dermatological Science</i> , 2019, 94, 284-289.	1.0	13
208	BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas. <i>PLoS ONE</i> , 2019, 14, e0216043.	1.1	8
209	The Changing Kinetics of Advanced Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 657.	2.0	0

#	ARTICLE	IF	CITATIONS
210	Clinical protein science in translational medicine targeting malignant melanoma. <i>Cell Biology and Toxicology</i> , 2019, 35, 293-332.	2.4	33
211	Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. <i>European Journal of Cancer</i> , 2019, 112, 9-11.	1.3	6
212	Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience. <i>Melanoma Research</i> , 2019, 29, 289-294.	0.6	5
213	A 10-year retrospective study of melanoma stage at diagnosis in the academic emergency hospital of Sibiu county. <i>Oncology Letters</i> , 2019, 17, 4145-4148.	0.8	7
214	Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. <i>Annals of Oncology</i> , 2019, 30, 804-814.	0.6	117
215	Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource. <i>Cancers</i> , 2019, 11, 280.	1.7	33
216	False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1860-1868.	0.7	29
217	Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma. <i>PLoS ONE</i> , 2019, 14, e0211504.	1.1	6
218	Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual. <i>JAMA Dermatology</i> , 2019, 155, 572.	2.0	2
219	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. <i>Annals of Oncology</i> , 2019, 30, 815-822.	0.6	77
220	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1314-1322.	3.0	35
222	Multispectral photoacoustic imaging for the detection of subclinical melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 1070-1076.	0.8	11
223	What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1355-1356.	0.8	7
224	Telomerase Expression in a Series of Melanocytic Neoplasms. <i>Actas Dermo-sifiliográficas</i> , 2019, 110, 212-219.	0.2	5
225	Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. <i>Scientific Reports</i> , 2019, 9, 5154.	1.6	12
226	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1299-1307.e7.	0.6	8
227	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 381-392.	1.0	62
228	Association of Indoor Tanning Exposure With Age at Melanoma Diagnosis and BRAF V600E Mutations. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1228-1231.	3.0	4

#	ARTICLE	IF	CITATIONS
229	Re: "Time to reconsider the role of sentinel lymph node biopsy in melanoma": Journal of the American Academy of Dermatology, 2023, 88, e25-e26.	0.6	3
230	Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Medicine, 2019, 8, 2146-2156.	1.3	74
231	NKG2D Polymorphism in Melanoma Patients from Southeastern Spain. Cancers, 2019, 11, 438.	1.7	6
232	Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. Cancer Immunology Research, 2019, 7, 841-852.	1.6	47
233	Unlocking the therapeutic potential of primary tumor-draining lymph nodes. Cancer Immunology, Immunotherapy, 2019, 68, 1681-1688.	2.0	56
234	TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk. Cancers, 2019, 11, 452.	1.7	17
235	Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Medicine, 2019, 8, 2205-2212.	1.3	58
236	Serum S100B Levels in Melanoma. Methods in Molecular Biology, 2019, 1929, 691-700.	0.4	8
237	Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma. Annals of Surgical Oncology, 2019, 26, 1494-1502.	0.7	25
238	Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncology, 2019, 15, 1207-1217.	1.1	59
239	Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case-control study. BMJ Open, 2019, 9, e025246.	0.8	4
240	Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. Journal of Investigative Dermatology, 2019, 139, 728-731.	0.3	8
241	Sentinel bruising as a presentation of metastatic melanoma. BMJ Case Reports, 2019, 12, e228114.	0.2	3
242	Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management. Seminars in Radiation Oncology, 2019, 29, 166-170.	1.0	3
243	How I treat metastatic melanoma. ESMO Open, 2019, 4, e000509.	2.0	2
244	Impact of general anaesthesia in overall and disease-free survival compared to other types of anaesthesia in patients undergoing surgery for cutaneous melanoma: a systematic review and meta-analysis protocol. BMJ Open, 2019, 9, e027993.	0.8	1
245	Targeting L-Lactate Metabolism to Overcome Resistance to Immune Therapy of Melanoma and Other Tumor Entities. Journal of Oncology, 2019, 2019, 1-12.	0.6	47
246	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Management, 2019, 6, MMT33.	0.1	6

#	ARTICLE	IF	CITATIONS
247	Vertical Growth Phase as a Prognostic Factor for Sentinel Lymph Node Positivity in Thin Melanomas. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 444e-445e.	0.7	0
248	Enhancing Case Capture, Quality, and Completeness of Primary Melanoma Pathology Records via Natural Language Processing. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-11.	1.0	11
249	Primary Melanoma: from History to Actual Debates. <i>Current Oncology Reports</i> , 2019, 21, 112.	1.8	8
250	Sentinel Lymph Node Biopsy in Patients With Acral Melanoma: Analysis of 201 Cases From the Brazilian National Cancer Institute. <i>Dermatologic Surgery</i> , 2019, 45, 1026-1034.	0.4	4
251	Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results. <i>Oncolmmunology</i> , 2019, 8, e1677139.	2.1	14
252	The Evolution of Adjuvant Therapy for Melanoma. <i>Current Oncology Reports</i> , 2019, 21, 106.	1.8	23
253	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 1905.	1.7	14
254	Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma. <i>Melanoma Research</i> , 2019, 29, 501-509.	0.6	12
255	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	0.6	16
256	Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 643-648.	0.6	11
257	“Personalized Excision” of Malignant Melanoma: Need for a Paradigm Shift in the Beginning Era of Personalized Medicine. <i>American Journal of Dermatopathology</i> , 2019, 41, 884-896.	0.3	12
258	Small and Isolated Immunohistochemistry-positive Cells in Melanoma Sentinel Lymph Nodes Are Associated With Disease-specific and Recurrence-free Survival Comparable to that of Sentinel Lymph Nodes Negative for Melanoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 755-765.	2.1	6
259	Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. <i>Melanoma Management</i> , 2019, 6, MMT32.	0.1	28
260	Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. <i>Oncology Reviews</i> , 2019, 13, 433.	0.8	9
261	Topical and intralesional therapies for in-transit melanoma. <i>Melanoma Management</i> , 2019, 6, MMT23.	0.1	4
262	Systemic therapies for unresectable locoregional melanoma: a significant area of need. <i>Melanoma Management</i> , 2019, 6, MMT25.	0.1	6
263	Locoregional melanoma: identifying optimal care in a rapidly changing landscape. <i>Melanoma Management</i> , 2019, 6, MMT22.	0.1	0
264	Prognosis and Management of Thick and Ultrathick Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 824-829.	0.6	11



#	ARTICLE	IF	CITATIONS
265	The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma Association with Clinical Outcome and Tumor Phenotypes. <i>Cancers</i> , 2019, 11, 1981.	1.7	16
266	Lymph node identification in skin malignancy using indocyanine green transcutaneously study. <i>Medicine (United States)</i> , 2019, 98, e17839.	0.4	2
267	Isolated Immunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1442-1444.	2.1	4
268	Reply: Vertical Growth Phase as a Prognostic Factor for Sentinel Lymph Node Positivity in Thin Melanomas: A Systematic Review and Meta-Analysis. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 445e-446e.	0.7	1
269	Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma. <i>Melanoma Research</i> , 2019, 29, 510-515.	0.6	12
270	Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 7585-7593.	3.2	17
271	Dibutyltin(IV) and Tributyltin(IV) Derivatives of meso-Tetra(4-sulfonatophenyl)porphine Inhibit the Growth and the Migration of Human Melanoma Cells. <i>Cells</i> , 2019, 8, 1547.	1.8	4
272	A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab. <i>Journal of Immunotherapy</i> , 2019, 42, 265-268.	1.2	11
273	Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. <i>American Journal of Dermatopathology</i> , 2019, 41, 264-272.	0.3	29
274	Relapse patterns in patients with local and regional cutaneous melanoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 412-419.	1.2	12
275	Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology. <i>Survey of Ophthalmology</i> , 2019, 64, 272-288.	1.7	25
276	Clinical implications of the eighth edition of the American Joint Committee on Cancer melanoma staging. <i>Journal of Surgical Oncology</i> , 2019, 119, 168-174.	0.8	15
277	Indications for the surgical resection of stage IV disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 249-261.	0.8	14
278	Malignant Skin Neoplasms and Associated Conditions. , 2019, , 135-170.		0
279	Metastatic Melanoma. , 2019, , 314-329.		1
280	Effectiveness of interventions to support the early detection of skin cancer through skin self-examination: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2019, 180, 1339-1347.	1.4	17
281	Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells. <i>Molecular Carcinogenesis</i> , 2019, 58, 588-602.	1.3	37
282	Current controversies in early-stage melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 15-25.	0.6	10



#	ARTICLE	IF	CITATIONS
283	Neoadjuvant Treatments for Advanced Resectable Melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 216-221.	0.8	7
284	Prognosis, Staging, and Reporting of Melanomas. , 2019, , 386-396.		4
285	Estudio de la expresión de telomerasa en una serie de neoplasias melanocíticas. <i>Actas Dermo-sifiliográficas</i> , 2019, 110, 212-219.	0.2	7
286	Tackling melanoma by adjuvant therapy: why, whom and how?. <i>British Journal of Dermatology</i> , 2019, 180, 1-2.	1.4	3
287	Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. <i>Melanoma Research</i> , 2019, 29, 1-12.	0.6	61
288	Subungual Melanoma of the Hand. <i>Annals of Surgical Oncology</i> , 2019, 26, 1035-1043.	0.7	28
289	Sentinel node for malignant melanoma: An observational study of a consecutive single centre experience. <i>European Journal of Surgical Oncology</i> , 2019, 45, 225-230.	0.5	4
290	Cutaneous Metastasis. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 173-197.	0.9	32
291	Cutaneous Melanoma—A Review in Detection, Staging, and Management. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 25-38.	0.9	85
292	Melanoma of unknown primary. <i>Journal of Surgical Oncology</i> , 2019, 119, 232-241.	0.8	21
293	Management of inâ€transit melanoma metastases: a review. <i>ANZ Journal of Surgery</i> , 2019, 89, 647-652.	0.3	18
294	Prognostic impact of regression in patients with primary cutaneous melanoma &gt;1Âmm in thickness. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 99-105.e5.	0.6	19
295	Microsatellitosis in Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 33-41.	0.7	11
296	Updates in Melanoma. <i>Dermatologic Clinics</i> , 2019, 37, 73-82.	1.0	57
297	Management of Early-Stage Melanoma. <i>Facial Plastic Surgery Clinics of North America</i> , 2019, 27, 35-42.	0.9	18
298	The Role of Sentinel Lymph Node Biopsy in the Management of Cutaneous Malignancies. <i>Facial Plastic Surgery Clinics of North America</i> , 2019, 27, 119-129.	0.9	4
299	Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study. <i>Future Oncology</i> , 2019, 15, 359-370.	1.1	11
300	Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilianâ€Dutch Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 395-405.	0.7	16

#	ARTICLE	IF	CITATIONS
301	Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma. PLoS ONE, 2019, 14, e0210399.	1.1	20
302	Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma. Cancer Letters, 2019, 446, 25-37.	3.2	28
303	Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. Immunotherapy, 2019, 11, 297-309.	1.0	22
304	Expression of Neural Crest Markers GLDC and ERFF1 is Correlated with Melanoma Prognosis. Cancers, 2019, 11, 76.	1.7	11
305	Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage IIâ€“III Melanoma. Clinical Cancer Research, 2019, 25, 2494-2502.	3.2	18
306	Harnessing autophagy to overcome mitogenâ€“activated protein kinase kinase inhibitorâ€“induced resistance in metastatic melanoma. British Journal of Dermatology, 2019, 180, 346-356.	1.4	23
307	PDâ€“L1 methylation regulates PDâ€“L1 expression and is associated with melanoma survival. Pigment Cell and Melanoma Research, 2019, 32, 435-440.	1.5	54
308	Molecular Testing for Cutaneous Melanoma: An Update and Review. Archives of Pathology and Laboratory Medicine, 2019, 143, 811-820.	1.2	19
309	Increased tumour cell <sc>PD</sc>â€“L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 667-675.	1.3	21
310	Association of Quality of Life With Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatology, 2019, 155, 85.	2.0	16
311	Inter-observer variation in the histopathology reports of head and neck melanoma; a comparison between the seventh and eighth edition of the AJCC staging system. European Journal of Surgical Oncology, 2019, 45, 235-241.	0.5	5
312	Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2019, 80, 208-250.	0.6	400
313	Evaluation of the agreement between TNM 7th and 8th in a populationâ€“based series of cutaneous melanoma. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 521-524.	1.3	7
314	Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. Methods in Molecular Biology, 2019, 1904, 83-108.	0.4	47
315	Current controversies in early-stage melanoma. Journal of the American Academy of Dermatology, 2019, 80, 1-12.	0.6	45
316	Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. Journal of Surgical Oncology, 2019, 119, 175-186.	0.8	32
317	Management of local or regional nonâ€“nodal disease. Journal of Surgical Oncology, 2019, 119, 187-199.	0.8	8
319	Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients. European Respiratory Journal, 2019, 53, 1801298.	3.1	27

#	ARTICLE	IF	CITATIONS
320	Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 149-157.e4.	0.6	72
321	Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. <i>Journal of Pathology</i> , 2019, 247, 539-551.	2.1	142
322	Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes. <i>British Journal of Surgery</i> , 2019, 106, 217-225.	0.1	34
323	Outcomes and Risk Factors in Patients with Multiple Primary Melanomas. <i>Journal of Investigative Dermatology</i> , 2019, 139, 195-201.	0.3	20
324	Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. <i>Australasian Journal of Dermatology</i> , 2019, 60, 75-76.	0.4	1
325	Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters. <i>Journal of Clinical Pathology</i> , 2019, 72, 265-270.	1.0	21
326	Stellenwert der chirurgischen Metastasenentfernung bei Hautmelanomen im Stadium IV. <i>Wiener Medizinische Wochenschrift</i> , 2019, 169, 331-338.	0.5	10
327	Aquaporin-1 Protein Expression of the Primary Tumor May Predict Cerebral Progression of Cutaneous Melanoma. <i>Pathology and Oncology Research</i> , 2020, 26, 405-410.	0.9	7
328	Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study. <i>International Journal of Cancer</i> , 2020, 146, 26-34.	2.3	28
329	Dermoscopic features in different dermatopathological stages of cutaneous melanomas. <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 677-684.	0.4	4
330	Robotic-Assisted Pelvic Lymphadenectomy for Metastatic Melanoma Results in Durable Oncologic Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 196-202.	0.7	6
331	The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). <i>Annals of Surgical Oncology</i> , 2020, 27, 15-21.	0.7	56
332	Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection. <i>Pharmacoeconomics - Open</i> , 2020, 4, 343-351.	0.9	4
333	MicroRNA Ratios Distinguish Melanomas from Nevi. <i>Journal of Investigative Dermatology</i> , 2020, 140, 164-173.e7.	0.3	32
334	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>Oncolmmunology</i> , 2020, 9, 1659093.	2.1	62
335	Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. <i>Cancer</i> , 2020, 126, 86-97.	2.0	113
336	Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 1-11.	3.3	13
337	Factors associated with sentinel lymph node status and prognostic role of completion lymph node dissection for thick melanoma. <i>European Journal of Surgical Oncology</i> , 2020, 46, 263-271.	0.5	16

#	ARTICLE	IF	CITATIONS
338	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , 2020, 33, 496-513.	2.9	19
339	Deep Adversarial Training for Multi-Organ Nuclei Segmentation in Histopathology Images. <i>IEEE Transactions on Medical Imaging</i> , 2020, 39, 3257-3267.	5.4	190
340	Concomitant <i>GNA11</i> and <i>SF3B1</i> mutations in two cases of melanoma associated with blue naevus. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 123-126.	0.6	1
341	Protein expression information of prostate infection based on data mining. <i>Journal of Infection and Public Health</i> , 2020, 13, 1533-1536.	1.9	0
342	The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 35-42.	0.7	4
343	Staging Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 29-41.	0.5	4
345	Cutaneous metastases: A great imitator. <i>Clinics in Dermatology</i> , 2020, 38, 216-222.	0.8	17
346	Surgical Management of Lymph Nodes in Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 71-90.	0.5	6
347	Nonsurgical Management of Lymph Node Basins in Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 91-107.	0.5	1
348	Surgical Considerations and Systemic Therapy of Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 141-159.	0.5	4
349	Reconstructive burden and financial implications of wider excision margins for invasive primary cutaneous melanoma. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 313-318.	0.5	2
350	The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 910-919.	0.6	10
351	Preferences for Immunotherapy in Melanoma: A Systematic Review. <i>Annals of Surgical Oncology</i> , 2020, 27, 571-584.	0.7	36
352	Immunohistochemical detectability of cyclooxygenase-2 expression in cells of human melanocytic skin lesions: A methodological review. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 363-380.	0.7	4
353	ASO Author Reflections: Important Factors for Adjuvant Immunotherapy Treatment Decisions for Stage II-IV Melanoma Patients and Their Clinicians. <i>Annals of Surgical Oncology</i> , 2020, 27, 585-586.	0.7	0
354	Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 956-966.	1.3	19
355	Role of Surgery for Metastatic Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 127-139.	0.5	19
356	A variant in <i>FTO</i> gene shows association with histological ulceration in cutaneous melanoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 98-101.	0.7	4

#	ARTICLE	IF	CITATIONS
357	Clinicopathological factors associated with death from thin (≤1.00 mm) melanoma. <i>British Journal of Dermatology</i> , 2020, 182, 927-931.	1.4	20
358	Primary malignant melanoma of the uterine cervix or vagina which were successfully treated with nivolumab. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 190-195.	0.6	15
359	Brain malignancies: Glioblastoma and brain metastases. <i>Seminars in Cancer Biology</i> , 2020, 60, 262-273.	4.3	208
360	A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. <i>British Journal of Dermatology</i> , 2020, 182, 1148-1157.	1.4	28
361	The Evolution of Melanoma – Moving beyond Binary Models of Genetic Progression. <i>Journal of Investigative Dermatology</i> , 2020, 140, 291-297.	0.3	7
362	Association of combined <sc>PD</sc>L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 984-994.	1.3	31
363	In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma. <i>Oncolmmunology</i> , 2020, 9, 1708066.	2.1	5
364	New biomarkers improve stratification of patients with melanoma. <i>British Journal of Dermatology</i> , 2020, 182, 5-6.	1.4	1
365	The challenge of identifying which stage III melanoma patients need adjuvant treatment and with what. <i>Annals of Oncology</i> , 2020, 31, 11-12.	0.6	2
366	Time-varying pattern of recurrence risk for localized melanoma in China. <i>World Journal of Surgical Oncology</i> , 2020, 18, 6.	0.8	6
367	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2915-2926.	0.7	11
368	Considering adjuvant therapy for stage II melanoma. <i>Cancer</i> , 2020, 126, 1166-1174.	2.0	32
369	Thick melanomas without lymph node metastases: A forgotten group with poor prognosis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 918-923.	0.5	4
370	Surgical Management of Primary Cutaneous Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 61-70.	0.5	23
371	Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. <i>Cancer</i> , 2020, 126, 775-781.	2.0	12
372	Melanoma Awareness Among Medical Students. <i>Journal of Cancer Education</i> , 2021, 36, 677-681.	0.6	8
374	An evaluation of encorafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 155-161.	0.9	11
375	Sentinel Node Identification in Melanoma: Current Clinical Impact, New Emerging SPECT Radiotracers and Technological Advancements. An Update of the Last Decade. <i>Current Radiopharmaceuticals</i> , 2020, 13, 32-41.	0.3	23

#	ARTICLE	IF	CITATIONS
376	Educational interventions for primary care providers to improve clinical skin examination for skin cancer. <i>Journal of the American Association of Nurse Practitioners</i> , 2020, 32, 369-379.	0.5	9
377	Is it Necessary to Perform Sentinel Lymph Node Biopsy in Thin Melanoma? A Retrospective Single Center Analysis. <i>Pathology and Oncology Research</i> , 2020, 26, 1861-1868.	0.9	16
378	Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 125, 38-45.	1.3	36
379	Long Non-Coding RNA-CASC15 Promotes Cell Proliferation, Migration, and Invasion by Activating Wnt/ $\beta$ 2-Catenin Signaling Pathway in Melanoma. <i>Pathobiology</i> , 2020, 87, 20-29.	1.9	22
380	External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?. <i>Melanoma Research</i> , 2020, 30, 185-192.	0.6	17
381	Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease. <i>British Journal of Dermatology</i> , 2020, 183, 559-563.	1.4	18
382	Melanoma pathology reporting and staging. <i>Modern Pathology</i> , 2020, 33, 15-24.	2.9	61
383	Blockade of CCR5 in melanoma: An alternative immune checkpoint modulator. <i>Experimental Dermatology</i> , 2020, 29, 196-196.	1.4	5
384	Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges. <i>Life Sciences</i> , 2020, 240, 117093.	2.0	12
386	Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. <i>Current Opinion in Oncology</i> , 2020, 32, 106-113.	1.1	52
387	Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 503-508.	2.1	75
388	Global and mitosis-specific interobserver variation in mitotic count scoring and implications for malignant melanoma staging. <i>Histopathology</i> , 2020, 76, 803-813.	1.6	6
389	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020, 16, 4429-4438.	1.1	59
390	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <i>Life</i> , 2020, 10, 219.	1.1	11
391	The Width of Invasion in Malignant Melanoma Is a Novel Prognostic Feature That Accounts for Outcome Better Than Breslow Thickness. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1522-1527.	2.1	4
392	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17687.	1.6	14
393	FRAME: Familial Risk Assessment of Melanoma—a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma. <i>Familial Cancer</i> , 2021, 20, 231-239.	0.9	6
394	Expression of IMP3 in a retrospective cohort of melanomas with selective lymph node biopsy. <i>Dermatologic Therapy</i> , 2020, 33, e14413.	0.8	1

#	ARTICLE	IF	CITATIONS
395	How does the mitotic index impact patients with T1 melanoma? Comparison between the 7th and 8th edition of the American Joint Committee on Cancer melanoma staging system. <i>Anais Brasileiros De Dermatologia</i> , 2020, 95, 691-695.	0.5	3
396	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448.	0.6	132
397	Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?. <i>Melanoma Management</i> , 2020, 7, MMT47.	0.1	24
398	Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. <i>European Journal of Cancer</i> , 2020, 140, 11-18.	1.3	31
399	Obesity attenuates the effect of sleep apnea on active TGF- $\beta$ 1 levels and tumor aggressiveness in patients with melanoma. <i>Scientific Reports</i> , 2020, 10, 15528.	1.6	8
400	Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 554-556.	0.2	1
402	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5926-5933.	3.2	41
403	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661.	1.3	11
404	Impact of Non-Steroidal Anti-Inflammatory Drugs on Recurrence and Survival after Melanoma Surgery: A Cohort Study. <i>Cancer Investigation</i> , 2020, 38, 415-423.	0.6	4
405	The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years. <i>Annals of Surgical Oncology</i> , 2020, 27, 4109-4119.	0.7	12
406	Targeted and immunotherapies in <i>BRAF</i> mutant melanoma: where we stand and what to expect. <i>British Journal of Dermatology</i> , 2021, 185, 253-262.	1.4	20
407	Anxiety and depression after diagnosis of high-risk primary cutaneous melanoma: a 4-year longitudinal study. <i>Journal of Cancer Survivorship</i> , 2020, 14, 712-719.	1.5	12
408	Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 547-554e1.	0.2	8
409	Immune Microenvironment Related Competitive Endogenous RNA Network as Powerful Predictors for Melanoma Prognosis Based on WGCNA Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 577072.	1.3	21
410	Locoregional Management of in-Transit Metastasis in Melanoma: An Ontario Health (Cancer Care) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.9	10
411	Risk prediction in cutaneous melanoma patients from their clinico-pathological features: superiority of clinical data over gene expression data. <i>Heliyon</i> , 2020, 6, e04811.	1.4	8
412	Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. <i>BMJ Open</i> , 2020, 10, e037857.	0.8	4
413	Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database. <i>European Journal of Dermatology</i> , 2020, 30, 389-396.	0.3	1



#	ARTICLE	IF	CITATIONS
414	Efficacy of Electrochemotherapy in the Treatment of Cutaneous Melanoma Metastases and Rare Non-melanoma Skin Cancer. <i>Anticancer Research</i> , 2020, 40, 6485-6492.	0.5	16
415	Mixed adenoneuroendocrine carcinoma of the hepatic bile duct: a case report and review of the literature. <i>BMC Gastroenterology</i> , 2020, 20, 399.	0.8	4
416	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	1.8	88
417	RAGE Signaling in Melanoma Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8989.	1.8	13
418	Enhancer of zeste 2 polycomb repressive complex 2 subunit polymorphisms in melanoma skin cancer risk. <i>Experimental Dermatology</i> , 2020, 29, 980-986.	1.4	1
419	Sentinel Node Status is the Most Important Prognostic Information for Clinical Stage IIB and IIC Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 4133-4140.	0.7	9
420	Early Cost-effectiveness Analysis of Electrochemotherapy as a Prospect Treatment Modality for Skin Melanoma. <i>Clinical Therapeutics</i> , 2020, 42, 1535-1548.e2.	1.1	6
421	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. <i>Cancer</i> , 2020, 126, 4717-4725.	2.0	14
422	Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma. <i>BMJ Case Reports</i> , 2020, 13, e235472.	0.2	0
423	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2020, 38, 3238-3240.	0.8	3
424	Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients. <i>Medicine (United States)</i> , 2020, 99, e21329.	0.4	17
425	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. <i>Cancers</i> , 2020, 12, 1994.	1.7	26
426	Comorbidity burden on receipt of adjuvant immunotherapy and survival in patients with stage III melanoma: an analysis of the National Cancer Database. <i>International Journal of Dermatology</i> , 2020, 59, 1381-1390.	0.5	3
427	Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 3234-3235.	0.8	6
428	Clinicoprognostic characteristics of cutaneous metastatic melanoma: a retrospective comparative study between acral and nonacral melanoma. <i>International Journal of Dermatology</i> , 2020, 59, 1249-1257.	0.5	0
429	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020, 16, 2165-2175.	1.1	20
430	ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2060.	1.0	6
431	Prognostic Gene Expression Profiling in Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 1004.	2.0	59



#	ARTICLE	IF	CITATIONS
432	ASO Author Reflections: Sentinel Node Biopsyâ€”Retirement Will Have to Wait. <i>Annals of Surgical Oncology</i> , 2020, 27, 4141-4142.	0.7	0
433	Clinical Development of BRAF plus MEK Inhibitor Combinations. <i>Trends in Cancer</i> , 2020, 6, 797-810.	3.8	169
434	How cancer registries can detect neoplasms in pathology laboratories that code with SNOMED CT terminology? An actual, simple and flexible solution. <i>International Journal of Medical Informatics</i> , 2020, 141, 104167.	1.6	5
435	â€œTo Anticipateâ€” Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1941.	1.7	4
436	Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim. <i>Journal of Clinical Oncology</i> , 2020, 38, 3237-3238.	0.8	1
437	The use of FDGâ€”PET/CT to detect early recurrence after resection of highâ€”risk stage III melanoma. <i>Journal of Surgical Oncology</i> , 2020, 122, 1328-1336.	0.8	4
438	Advances in the Systemic Treatment of Melanoma Brain Metastases. , 2020, , .		0
440	Expression and clinical significance of five major genes in cutaneous melanoma based on TCGA database. <i>Human Pathology: Case Reports</i> , 2020, 21, 200411.	0.2	0
441	Without Missing a Beat: Absence of Cilia Informs the Diagnosis of Histopathologically Challenging Spitzoid Melanocytic Neoplasms. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1320-1323.	0.3	1
442	Proangiogenic factor midkine is increased in melanoma patients with sleep apnea and induces tumor cell proliferation. <i>FASEB Journal</i> , 2020, 34, 16179-16190.	0.2	11
443	Novel application of adipose-derived mesenchymal stem cells via producing antiangiogenic factor TSP-1 in lung metastatic melanoma animal model. <i>Biologicals</i> , 2020, 68, 9-18.	0.5	14
444	Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 18682.	1.6	40
445	Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance. <i>Journal of Surgical Oncology</i> , 2020, 122, 1770-1777.	0.8	23
446	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	0.6	69
447	Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. , 2020, 8, e001193.		28
448	The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression. <i>Scientific Reports</i> , 2020, 10, 14372.	1.6	31
449	Diagnostics of Melanocytic Skin Tumours by a Combination of Ultrasonic, Dermatoscopic and Spectrophotometric Image Parameters. <i>Diagnostics</i> , 2020, 10, 632.	1.3	11
450	The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2147-2153.	0.5	13

#	ARTICLE	IF	CITATIONS
451	Updates in the evidence-based management of cutaneous melanoma. <i>Head and Neck</i> , 2020, 42, 3396-3404.	0.9	3
453	Development and validation of prognostic nomogram in patients with nonmetastatic malignant melanoma: a SEER population-based study. <i>Cancer Medicine</i> , 2020, 9, 8562-8570.	1.3	12
454	PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. <i>OncoImmunology</i> , 2020, 9, 1786888.	2.1	29
455	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	0.8	192
456	Intraventricular metastatic melanoma: A case report and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1757-1764.	0.2	1
457	Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells. <i>Molecular Carcinogenesis</i> , 2020, 59, 1256-1268.	1.3	11
458	Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 455-464.	0.6	4
459	MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project. <i>Melanoma Research</i> , 2020, 30, 500-510.	0.6	6
460	Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. <i>Melanoma Management</i> , 2020, 7, MMT43.	0.1	7
461	Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives. <i>Cancers</i> , 2020, 12, 2362.	1.7	22
462	Surgical and Pathological Documentation and Compliance With Consensus Guidelines in Patients With Thin Melanoma at a Community Teaching Hospital. <i>American Surgeon</i> , 2020, , 000313482097335.	0.4	0
463	The Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival. <i>Cancers</i> , 2020, 12, 3754.	1.7	3
465	Skin melanoma survival is not superior in females in the new stage IIID of the 8th edition of the staging system: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database. <i>Annals of Translational Medicine</i> , 2020, 8, 1381-1381.	0.7	7
466	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection. <i>Cancers</i> , 2020, 12, 3793.	1.7	12
467	Circulating Melanoma-Derived Extracellular Vesicles: Impact on Melanoma Diagnosis, Progression Monitoring, and Treatment Response. <i>Pharmaceuticals</i> , 2020, 13, 475.	1.7	13
468	The tumor genetics of acral melanoma: What should a dermatologist know?. <i>JAAD International</i> , 2020, 1, 135-147.	1.1	18
469	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22
470	Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 20, 100891.	0.4	14

#	ARTICLE	IF	CITATIONS
471	Association of HERV-K and LINE-1 hypomethylation with reduced disease-free survival in melanoma patients. <i>Epigenomics</i> , 2020, 12, 1689-1706.	1.0	11
472	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. <i>Frontiers in Immunology</i> , 2020, 11, 574271.	2.2	112
473	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). <i>Melanoma Management</i> , 2020, 7, MMT41.	0.1	3
475	Development and validation of a Brazilian nomogram to assess sentinel node biopsy positivity in melanoma. <i>Tumori</i> , 2021, 107, 440-445.	0.6	0
476	The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma—A Nation-Wide Swedish Population-Based Retrospective Register Study. <i>Cancers</i> , 2020, 12, 3228.	1.7	9
477	Lymphatic invasion in acral and non-acral melanoma: a comparative, clinicoprognostic study of primary cutaneous melanoma according to tumour site. <i>Pathology</i> , 2020, 52, 670-675.	0.3	7
478	Fine Needle Aspiration Cytology (FNAC) for Chinese Patients With Acral and Cutaneous Melanoma: Accuracy and Safety Analysis From a Single Institution. <i>Frontiers in Oncology</i> , 2020, 10, 1724.	1.3	0
479	Primary dermal melanoma: clinical behaviour, prognosis and treatment. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2131-2139.	0.5	5
480	Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e351-e353.	1.3	40
481	Acral lentiginous melanoma: Clinicopathologic and survival differences according to tumour location. <i>Australasian Journal of Dermatology</i> , 2020, 61, 312-317.	0.4	7
482	Supportive care and unmet needs in patients with melanoma: a mixed-methods systematic review. <i>Supportive Care in Cancer</i> , 2020, 28, 3489-3501.	1.0	18
484	Prognostic significance of tumor size for primary invasive cutaneous melanoma: A population-based study, 2004-2016. <i>Cancer Medicine</i> , 2020, 9, 4561-4571.	1.3	13
485	Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma. <i>Molecular Cancer</i> , 2020, 19, 84.	7.9	99
486	ASO Author Reflections: The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients: A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2201-2202.	0.7	0
487	“Primum non nocere”: how harmless is routine wide local excision for AJCC stage IA melanoma?. <i>Annals of the Royal College of Surgeons of England</i> , 2020, 102, 483-487.	0.3	6
488	Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study. <i>Molecular Oncology</i> , 2020, 14, 1705-1718.	2.1	19
489	Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. <i>Cancer</i> , 2020, 126, 3900-3906.	2.0	62
490	In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma. , 2020, 8, e000204.		35

#	ARTICLE	IF	CITATIONS
491	Tumor growth rate as a prognostic factor of acral melanoma in a Korean population. <i>Medicine (United States)</i> , 2020, 99, e19936.	0.4	1
492	Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. <i>Australasian Journal of Dermatology</i> , 2020, 61, 203-209.	0.4	4
493	Efficacy of immune checkpoint inhibitors for in-transit melanoma. , 2020, 8, e000440.		18
494	Speed rate (SR) as a new dynamic index of melanoma behavior. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 709-718.	1.5	11
495	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients – A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2188-2200.	0.7	4
496	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020, 133, 94-103.	1.3	13
497	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node–positive melanoma without the need for completion lymph node dissection. <i>European Journal of Cancer</i> , 2020, 134, 9-18.	1.3	11
498	Mixed Response to Immunotherapy in Patients with Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3488-3497.	0.7	24
499	Circular RNAs: new genetic tools in melanoma. <i>Biomarkers in Medicine</i> , 2020, 14, 563-571.	0.6	16
500	Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. , 2020, 8, e000395.		9
501	Outcomes after progression of disease with anti–PD–1/PD–L1 therapy for patients with advanced melanoma. <i>Cancer</i> , 2020, 126, 3448-3455.	2.0	20
502	Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 87, 102032.	3.4	13
503	Management of Regional Nodal Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 415-431.	0.6	1
504	Role of Surgery in Stage IV Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 485-495.	0.6	8
505	Neoadjuvant Therapy for Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 445-453.	0.6	2
506	Tspan8 Drives Melanoma Dermal Invasion by Promoting ProMMP-9 Activation and Basement Membrane Proteolysis in a Keratinocyte-Dependent Manner. <i>Cancers</i> , 2020, 12, 1297.	1.7	16
507	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020, 38, 2543-2551.	0.8	40
508	Sentinel Lymph Node Biopsy for Melanoma: Buggy Whip or Roller Bearing?. <i>Annals of Surgical Oncology</i> , 2020, 27, 2586-2588.	0.7	1

#	ARTICLE	IF	CITATIONS
509	Quality assurance in melanoma care: guideline-based quality indicators for melanoma – implementation, evaluation and update process. JDDG - Journal of the German Society of Dermatology, 2020, 18, 848-857.	0.4	7
510	Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic. British Journal of Dermatology, 2020, 183, 792-794.	1.4	58
511	Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma. Dermatology and Therapy, 2020, 10, 985-999.	1.4	6
512	Reply to Problematic methodology in a systematic review and meta-analysis of DecisionDx-Melanoma. Journal of the American Academy of Dermatology, 2020, 83, e359-e360.	0.6	1
513	The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020. Cancers, 2020, 12, 1543.	1.7	18
514	Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Annals of Oncology, 2020, 31, 1198-1206.	0.6	96
515	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. Advances in Medical Sciences, 2020, 65, 316-323.	0.9	12
516	Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost. Annals of Surgical Oncology, 2020, 27, 5248-5256.	0.7	12
517	Diagnosis of Cutaneous Melanoma: the Gap Between the Knowledge of General Practitioners and Dermatologists in a Brazilian Population. Journal of Cancer Education, 2020, 35, 819-825.	0.6	4
518	Regional nodal metastasis and 5-year survival in patients with thin melanoma in Queensland: a population-based study. ANZ Journal of Surgery, 2020, 90, 503-507.	0.3	3
519	Statins may reduce disease recurrence in patients with ulcerated primary melanoma. British Journal of Dermatology, 2020, 183, 1049-1055.	1.4	10
520	Whole transcriptome signature for prognostic prediction (WTSP): application of whole transcriptome signature for prognostic prediction in cancer. Laboratory Investigation, 2020, 100, 1356-1366.	1.7	1
521	Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity. Seminars in Cancer Biology, 2022, 79, 68-82.	4.3	15
522	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. BMJ Open, 2020, 10, e032636.	0.8	6
523	Isolated limb infusion: Institutional protocol and implementation. Journal of Surgical Oncology, 2020, 122, 99-105.	0.8	7
524	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. Frontiers in Oncology, 2020, 10, 202.	1.3	6
525	Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Cutaneous or Mucosal Melanoma: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. Current Oncology, 2020, 27, 43-52.	0.9	12
526	Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. Journal of Clinical Oncology, 2020, 38, 1591-1601.	0.8	50

#	ARTICLE	IF	CITATIONS
527	Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective. <i>Cancers</i> , 2020, 12, 554.	1.7	15
528	Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 493-504.	3.3	30
529	Challenges in sentinel node pathology in the era of adjuvant treatment. <i>Journal of Surgical Oncology</i> , 2020, 122, 964-972.	0.8	7
530	Adjuvant Therapy for Cutaneous Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 455-465.	0.6	1
531	Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice. <i>Advances in Therapy</i> , 2020, 37, 3619-3629.	1.3	5
532	Evaluation of the Merits and Limitations of Evidence-Based Medicine. <i>JAMA Dermatology</i> , 2020, 156, 924.	2.0	0
533	20/20 in 2020: seeking clarity on the management of stage III melanoma in a rapidly changing treatment environment. <i>Annals of Translational Medicine</i> , 2020, 8, 776-776.	0.7	0
534	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.	1.4	31
535	Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. <i>Cancer Treatment Reviews</i> , 2020, 88, 102060.	3.4	27
536	Effect of delay between nuclear medicine scanning and sentinel node biopsy on outcome in patients with cutaneous melanoma. <i>British Journal of Surgery</i> , 2020, 107, 669-676.	0.1	7
537	Effect of a Skin Self-monitoring Smartphone Application on Time to Physician Consultation Among Patients With Possible Melanoma. <i>JAMA Network Open</i> , 2020, 3, e200001.	2.8	20
538	Combination of cyclophosphamide and shengbai decoction has synergistic effect against melanoma. <i>Biomedicine and Pharmacotherapy</i> , 2020, 126, 109866.	2.5	2
539	Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort. <i>Journal of Women's Health</i> , 2020, 29, 1160-1167.	1.5	21
540	The prognostic significance of microsatellites in cutaneous melanoma. <i>Modern Pathology</i> , 2020, 33, 1369-1379.	2.9	13
541	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 875-885.	3.0	20
542	Long-term deaths from melanoma according to tumor thickness at diagnosis. <i>International Journal of Cancer</i> , 2020, 147, 1391-1396.	2.3	16
543	Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain. <i>Frontiers in Immunology</i> , 2020, 11, 120.	2.2	28
544	Sentinel node tumor burden in prediction of prognosis in melanoma patients. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 365-376.	1.7	5



#	ARTICLE	IF	CITATIONS
545	Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy. <i>International Journal of Cancer</i> , 2020, 147, 1707-1714.	2.3	14
546	Real-world outcomes of melanoma surveillance using the MoleMap NZ telemedicine platform. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 596-603.	0.6	8
547	Does the time interval between sentinel lymph node biopsy and completion lymph node dissection affect outcome in malignant melanoma? A retrospective cohort study. <i>International Journal of Surgery</i> , 2020, 75, 160-164.	1.1	3
548	The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 500-522.	1.2	239
549	Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage III-IV M1c melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 759-769.	2.0	20
550	Internal Pathology Review of Invasive Melanoma: An Academic Institution Experience. <i>Journal of Surgical Research</i> , 2020, 250, 97-101.	0.8	1
551	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	1.3	133
552	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. <i>Nature Cancer</i> , 2020, 1, 197-209.	5.7	30
553	Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. <i>Journal of the National Cancer Institute</i> , 2020, 112, 921-928.	3.0	32
554	Staging for Melanoma - Toward a New Paradigm?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 873-874.	3.0	2
555	Anti-PD-1 and Novel Combinations in the Treatment of Melanoma – An Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 223.	1.0	95
556	Biomarkers for Melanoma. , 2020, , 73-104.		0
557	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	0.8	23
558	The miRNAs Role in Melanoma and in Its Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 878.	1.8	50
559	Neoadjuvant checkpoint blockade for cancer immunotherapy. <i>Science</i> , 2020, 367, .	6.0	553
560	Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma. <i>Cancer Research</i> , 2020, 80, 1078-1087.	0.4	18
561	A novel RNA sequencing-based prognostic nomogram to predict survival for patients with cutaneous melanoma. <i>Medicine (United States)</i> , 2020, 99, e18868.	0.4	15
562	Who dies from thin melanoma?. <i>British Journal of Dermatology</i> , 2020, 182, 827-828.	1.4	1

#	ARTICLE	IF	CITATIONS
563	Acral lentiginous melanoma: a single-centre retrospective review of four decades in East-Central Europe. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2004-2010.	1.3	12
564	Prevention versus early detection for long-term control of melanoma and keratinocyte carcinomas: a cost-effectiveness modelling study. <i>BMJ Open</i> , 2020, 10, e034388.	0.8	18
565	Technological advances for the detection of melanoma. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 996-1004.	0.6	20
566	Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics. <i>Frontiers in Genetics</i> , 2020, 11, 221.	1.1	33
568	Oncolytic Viruses for the Treatment of Metastatic Melanoma. Current Treatment Options in Oncology, 2020, 21, 26.	1.3	21
569	Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 745-753.	0.6	50
570	Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 960.	1.7	25
571	A twelve-gene signature for survival prediction in malignant melanoma patients. <i>Annals of Translational Medicine</i> , 2020, 8, 312-312.	0.7	15
572	Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , 2020, 12, 1027.	1.7	17
573	Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 403-413.	1.1	2
574	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. , 2020, 8, e000333.		55
575	Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2227-2232.	3.3	8
576	Demographic, Clinical, and Pathologic Features of Patients With Cutaneous Melanoma: Final Analysis of the Brazilian Melanoma Group Database. <i>JCO Global Oncology</i> , 2020, 6, 575-582.	0.8	5
577	Melanoma of unknown primary in the pancreas: should it be considered primary?. <i>BMC Surgery</i> , 2020, 20, 76.	0.6	6
578	The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019. <i>Journal of Translational Medicine</i> , 2020, 18, 171.	1.8	2
579	Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. <i>JCO Precision Oncology</i> , 2020, 4, 319-334.	1.5	67
580	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 4414-4425.	3.2	70
581	Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1754-1758.	0.5	2



#	ARTICLE	IF	CITATIONS
582	Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 888.	1.7	8
583	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193
584	Survival in 31,670 patients with thin melanomas: a Swedish population-based study*. <i>British Journal of Dermatology</i> , 2021, 184, 60-67.	1.4	15
585	Oncological outcome of videoscopic groin dissection for lymph node metastasis from melanoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 2576-2582.	1.3	4
586	Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 1029-1038.	0.7	4
587	Immune metabolism in PD-1 blockade-based cancer immunotherapy. <i>International Immunology</i> , 2021, 33, 17-26.	1.8	26
588	Melanoma of the External Auditory Canal: A Review of Seven Cases at a Tertiary Care Referral Center. <i>Laryngoscope</i> , 2021, 131, 165-172.	1.1	9
589	Immunotherapy for advanced melanoma: current situation in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 3-9.	0.6	11
590	Survival Outcomes Following Lymph Node Biopsy in Thin Melanoma—A Propensity-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 1634-1641.	0.7	4
591	Extent of ulceration in cutaneous melanoma: is this biomarker ready for primetime?. <i>British Journal of Dermatology</i> , 2021, 184, 192-193.	1.4	0
593	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 475-483.	2.6	45
594	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	2.9	27
596	Patient preferences for treatment of advanced melanoma: impact of comorbidities. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 58-70.	0.4	7
597	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. <i>British Journal of Surgery</i> , 2021, 108, 550-553.	0.1	7
598	Indoor tanning exposure in association with multiple primary melanoma. <i>Cancer</i> , 2021, 127, 560-568.	2.0	8
599	Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage III patients. <i>European Journal of Cancer</i> , 2021, 143, 11-18.	1.3	12
600	Five-year survival in patients with nodular and superficial spreading melanomas in the US population. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1015-1022.	0.6	23
601	Correlation between ferromagnetic and isotopic tracers for sentinel lymph node detection in cutaneous melanoma: IMINEM study. <i>Journal of Surgical Oncology</i> , 2021, 123, 654-659.	0.8	4

#	ARTICLE	IF	CITATIONS
602	BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1635-1647.	2.0	13
603	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administrationâ€™Melanoma Research Alliance Public Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 394-401.	3.2	5
604	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. <i>Australasian Journal of Dermatology</i> , 2021, 62, 168-176.	0.4	3
605	Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux. <i>Pharmacological Research</i> , 2021, 163, 105295.	3.1	51
606	State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1-27.	0.9	4
607	Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1287-1295.	3.2	2
608	Adjuvant Therapy of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 73-84.	0.9	2
609	Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3501-3510.	0.7	13
610	Groin dissections in skin cancer: Effect of a change in prophylactic antibiotic protocol. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, 74, 1553-1561.	0.5	1
611	The use of indocyanine green and near-infrared fluorescence imaging to assist sentinel lymph node biopsy in cutaneous melanoma: A systematic review. <i>European Journal of Surgical Oncology</i> , 2021, 47, 935-941.	0.5	12
612	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2021, 232, 424-431.	0.2	14
613	Stage IIIa Melanoma and Impact of Multiple Positive Lymph Nodes on Survival. <i>Journal of the American College of Surgeons</i> , 2021, 232, 517-524e1.	0.2	4
615	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	0.7	8
616	Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis. <i>Journal of Histochemistry and Cytochemistry</i> , 2021, 69, 203-218.	1.3	0
617	Ultrasound Examination of the Lymphatic Drainage Area and Regional Lymph Nodes in Melanoma Patients with In-Transit Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 1625-1631.	0.7	7
618	ASO Author Reflections: Ultrasound Assessment of the Lymphatic Drainage Area in Melanoma Patients With In-Transit Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 1632-1633.	0.7	2
619	Applying adjuvant therapy for melanoma into clinical practice. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 129-133.	1.1	1
620	Surgical treatment of melanoma metastases to the small bowel: A single cancer referral center real-life experience. <i>European Journal of Surgical Oncology</i> , 2021, 47, 409-415.	0.5	3

#	ARTICLE	IF	CITATIONS
621	3D wide-field multispectral photoacoustic imaging of human melanomas <i>in vivo</i> : a pilot study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 669-676.	1.3	67
622	The role of sentinel lymph node status performed in melanoma patients with local recurrence or in transit metastasis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1152-1156.	0.5	0
623	The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 629-640.	1.5	6
624	Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 475-483.	2.0	6
625	Multiple combinations of melanocytic and vascular endothelial markers enhance the detection rate of lymphovascular invasion in cutaneous melanoma. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 472-478.	0.7	2
626	Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management. <i>Annals of Surgical Oncology</i> , 2021, 28, 1642-1653.	0.7	11
627	Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 104-109.	0.8	3
628	Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma*. <i>British Journal of Dermatology</i> , 2021, 184, 944-951.	1.4	26
629	Phenotypic Characteristics and Melanoma Thickness in Women. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00446.	0.6	2
630	Practical Management of Melanoma. , 2021, , 241-256.		0
631	A polymer-lipid membrane artificial cell nanocarrier containing enzyme oxygen biotherapeutic inhibits the growth of B16F10 melanoma in 3D culture and in a mouse model. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2021, 49, 461-470.	1.9	3
632	Primary melanoma of the oral cavity: A multi-institutional retrospective analysis in Brazil. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2021, 26, e379-e386.	0.7	7
633	Molecular Landscape Profile of Melanoma. , 2021, , 31-55.		0
634	ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4590-4591.	0.7	0
635	Anoikis Resistance in Melanoma. , 2021, , 137-160.		1
636	Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00502.	0.6	13
637	Regional lymph node infiltration and thick lesions are associated with poor prognosis in high-risk resected melanomas: A retrospective cohort study. <i>Annals of Medicine and Surgery</i> , 2021, 61, 132-138.	0.5	2
638	Surgical Approach to Cutaneous Malignancy with Systemic Implications. , 2021, , 117-147.		0

#	ARTICLE	IF	CITATIONS
639	Disease Progression in Cutaneous Squamous Cell Carcinoma Patients With Satellitosis and In-transit Metastasis. <i>Anticancer Research</i> , 2021, 41, 289-295.	0.5	8
641	Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 215-221.	0.4	5
642	YY1 is a potential key player in the pathogenesis of malignant melanoma. , 2021, , 163-169.		1
643	Clinical Suspicion Sensitivity of Nodular and Superficial Spreading Melanoma. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00427.	0.6	4
644	Pembrolizumab in Melanoma: From Care to Cure. , 2021, , 249-264.		1
645	Pathology of Melanoma and Skin Carcinomas. , 2021, , 3-30.		2
647	Novel Prognostic Models Predicting the Cancer-Specific Survival in Patients with Cutaneous Melanoma Based on Metastatic Lymph Node Status. <i>Annals of Surgical Oncology</i> , 2021, 28, 4572-4581.	0.7	1
648	GINS2 was regulated by lncRNA XIST/miR-23a-3p to mediate proliferation and apoptosis in A375 cells. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1455-1465.	1.4	12
649	Standardized Method for Defining a 1-mm <sup>2</sup> Region of Interest for Calculation of Mitotic Rate on Melanoma Whole Slide Images. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1255-1263.	1.2	6
650	Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4582-4589.	0.7	13
651	National Review of Melanomas in Turkey and Comparison with Clinicopathological Features of Melanomas Diagnosed at a Northwestern Academic Tertiary Center. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 104-116.	0.3	0
652	Protocol for the Histologic Diagnosis of Cutaneous Melanoma: Consensus Statement of the Spanish Society of Pathology and the Spanish Academy of Dermatology and Venereology (AEDV) for the National Cutaneous Melanoma Registry. <i>Actas Dermo-sifiliográficas</i> , 2021, 112, 32-43.	0.2	1
653	Brain Tumor Microenvironment and Angiogenesis in Melanoma Brain Metastases. <i>Frontiers in Oncology</i> , 2020, 10, 604213.	1.3	13
654	Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4561-4569.	0.7	11
655	Neoadjuvant and Adjuvant Therapies of Melanoma. , 2021, , 401-415.		0
657	Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV). <i>Actas Dermo-sifiliográficas</i> , 2021, 112, 142-152.	0.2	2
658	Novel oxidative stress-related prognostic biomarkers for melanoma associated with tumor metastasis. <i>Medicine (United States)</i> , 2021, 100, e24866.	0.4	8
659	Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma. <i>Cancers</i> , 2021, 13, 731.	1.7	12

#	ARTICLE	IF	CITATIONS
660	Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. <i>Cells</i> , 2021, 10, 327.	1.8	37
661	Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 583-590.	1.1	4
662	The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population. <i>Medicine (United States)</i> , 2021, 100, e24840.	0.4	4
663	Adjuvant immunotherapy for melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 789-797.	0.8	20
664	Prevalence of skin examination behaviours among Australians over time. <i>Cancer Epidemiology</i> , 2021, 70, 101874.	0.8	11
665	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2021, 157, 166.	2.0	21
666	Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina. <i>Oncology and Therapy</i> , 2021, 9, 167-185.	1.0	3
667	Microsimulation Model for Evaluating the Cost-Effectiveness of Surveillance in <i>BAP1</i> Pathogenic Variant Carriers. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 143-154.	1.0	7
668	Melanoma of unknown primary: New perspectives for an old story. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103208.	2.0	37
669	Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. <i>ESMO Open</i> , 2021, 6, 100002.	2.0	12
670	Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. <i>Frontiers in Oncology</i> , 2020, 10, 626129.	1.3	48
671	Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. <i>Scientific Reports</i> , 2021, 11, 2809.	1.6	20
672	Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients. <i>Cells</i> , 2021, 10, 422.	1.8	6
673	Early detection of melanoma in specialised primary care practice in Australia. <i>Cancer Epidemiology</i> , 2021, 70, 101872.	0.8	5
674	Checkpoint inhibitor-induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin's lymphoma. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 127-134.	0.5	1
675	Clinical performance of a novel hyperspectral imaging device for cutaneous melanoma and pigmented skin lesions in Caucasian skin. <i>Skin Research and Technology</i> , 2021, 27, 803-809.	0.8	3
676	Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 943-944.	0.8	2
677	Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFN± in melanoma. <i>Translational Oncology</i> , 2021, 14, 101014.	1.7	13

#	ARTICLE	IF	CITATIONS
678	Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study. <i>European Journal of Cancer</i> , 2021, 145, 29-37.	1.3	12
679	Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	48
680	Analysis of malignant melanoma risk and outcomes in solid organ transplant recipients: Assessment of transplant candidacy and the potential role of checkpoint inhibitors. <i>Clinical Transplantation</i> , 2021, 35, e14264.	0.8	3
681	Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 873-878.	0.6	2
682	Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients. <i>Acta Oncologica</i> , 2021, 60, 803-807.	0.8	4
683	Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e210980.	2.8	16
684	Surgery vs non-surgery in cutaneous melanoma based on SEER database. <i>Medicine (United States)</i> , 2021, 100, e25120.	0.4	0
685	Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners. <i>Patient</i> , 2021, 14, 635-647.	1.1	8
686	Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 6168-6176.	0.7	12
687	Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. <i>Cancers</i> , 2021, 13, 1383.	1.7	120
688	A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas. <i>Frontiers in Oncology</i> , 2021, 11, 636057.	1.3	8
689	Synthesis and Pharmacological In Vitro Investigations of Novel Shikonin Derivatives with a Special Focus on Cyclopropane Bearing Derivatives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2774.	1.8	9
690	Differences in Melanoma Between Canada and New South Wales, Australia: A Population-Based Genes, Environment, and Melanoma (GEM) Study. <i>JID Innovations</i> , 2021, 1, 100002.	1.2	1
691	A review of the AJCC melanoma staging system in the TNM classification (eighth edition). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 671-674.	0.6	8
692	Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [18F]FDG PET/CT. <i>European Radiology</i> , 2021, 31, 8011-8020.	2.3	12
693	Different progression pattern between acral and nonacral melanoma: A retrospective, comparative, clinicoprognostic study of 492 cases of primary cutaneous melanoma according to tumor site. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 87, 498-508.	0.2	4
694	Ultraviolet radiation and risk of cutaneous melanoma and squamous cell carcinoma in males and females in the Norwegian Offshore Petroleum Workers cohort. <i>American Journal of Industrial Medicine</i> , 2021, 64, 496-510.	1.0	7
695	Dermoscopy of early melanomas: variation according to the anatomic site. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	5



#	ARTICLE	IF	CITATIONS
696	Evidence for continuity of interstitial spaces across tissue and organ boundaries in humans. <i>Communications Biology</i> , 2021, 4, 436.	2.0	33
697	Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: an observational multicentric study in 443 patients with melanoma. <i>British Journal of Dermatology</i> , 2021, 185, 756-763.	1.4	6
698	Sentinel node biopsy for primary cutaneous melanoma. <i>Annals of Oncology</i> , 2021, 32, 290-292.	0.6	8
699	SEOM clinical guideline for the management of cutaneous melanoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 948-960.	1.2	22
700	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	2.0	6
701	The incidence of skin melanoma in Gran Canaria (Canary Islands, Spain) is lower than expected in Southern Europe despite high-risk environmental conditions: an island-wide cross-sectional study. <i>Cancer Causes and Control</i> , 2021, 32, 525-535.	0.8	4
702	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021, 39, 944-946.	0.8	1
703	Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2021, 13, 1489.	1.7	7
704	Recent advancements in melanoma management. <i>Internal Medicine Journal</i> , 2021, 51, 327-333.	0.5	4
705	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. <i>Annals of Oncology</i> , 2021, 32, 375-383.	0.6	25
706	Management of Nail Unit Melanoma. <i>Dermatologic Clinics</i> , 2021, 39, 269-280.	1.0	9
707	Neoadjuvant Cytorreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389.	2.1	28
708	Clinical Significance of Tumor Microenvironment in Acral Melanoma: A Large Single-Institution Study of Caucasians. <i>Journal of Clinical Medicine</i> , 2021, 10, 1452.	1.0	4
709	The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 329-342.	0.5	1
710	Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3704-e3713.	1.8	98
711	Validation of CP&GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study. <i>International Journal of Dermatology</i> , 2021, 60, 851-856.	0.5	19
712	Estimating the potential impact of interventions to reduce over&calling and under&calling of melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1519-1527.	1.3	3
713	Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects. <i>Frontiers in Medicine</i> , 2021, 8, 642380.	1.2	28

#	ARTICLE	IF	CITATIONS
714	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. <i>Journal of Clinical Oncology</i> , 2021, 39, 1243-1252.	0.8	28
715	A multicentre study of naevus-associated melanoma vs. <i>de novo</i> melanoma, tumour thickness and body site differences*. <i>British Journal of Dermatology</i> , 2021, 185, 101-109.	1.4	13
716	Age and Mitogenicity are Important Predictors of Sentinel Lymph Node Metastasis in T1a Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4777-4779.	0.7	4
717	Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 2641-2648.	0.3	3
718	Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. <i>Cancers</i> , 2021, 13, 1819.	1.7	16
719	Risk factors and patterns of recurrence after sentinel lymph node biopsy for thin melanoma. <i>Archives of Dermatological Research</i> , 2022, 314, 285-292.	1.1	0
720	Expression of SEC62 Oncogene in Benign, Malignant and Borderline Melanocytic Tumors—Unmasking the Wolf in Sheep's Clothing?. <i>Cancers</i> , 2021, 13, 1645.	1.7	10
721	Active surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned and still learning. <i>Cancer</i> , 2021, 127, 2177-2180.	2.0	1
722	Comparing the characteristics and predicting the survival of patients with head and neck melanoma versus body melanoma: a population-based study. <i>BMC Cancer</i> , 2021, 21, 420.	1.1	15
723	The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of <i>CDKN2A</i> and <i>CDK4</i> . <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 676-681.	1.1	3
724	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021, 19, 142.	1.8	1
725	Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4561.	1.8	21
726	Nucleosome assembly protein 1-like 4, a new therapeutic target for proliferation and invasion of melanoma cells. <i>Journal of Dermatological Science</i> , 2021, 102, 16-24.	1.0	2
727	Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. <i>Cancers</i> , 2021, 13, 2282.	1.7	6
728	Early time to recurrence predicts worse survival in patients with localized or regionally advanced cutaneous melanoma. <i>Dermatologic Therapy</i> , 2021, 34, e14981.	0.8	1
729	In-transit metastatic cutaneous melanoma: current management and future directions. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 201-211.	1.7	6
730	Proposed quality performance indicators of sentinel lymph node biopsy for cutaneous melanoma. <i>ANZ Journal of Surgery</i> , 2021, , .	0.3	1
731	Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis. <i>Journal of Molecular Medicine</i> , 2021, 99, 1279-1291.	1.7	3



#	ARTICLE	IF	CITATIONS
732	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. American Journal of Clinical Dermatology, 2021, 22, 511-522.	3.3	6
733	Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies. Frontiers in Oncology, 2021, 11, 635488.	1.3	36
734	The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden. Cancers, 2021, 13, 2456.	1.7	2
735	Predicting sentinel node positivity in patients with melanoma: external validation of a risk prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort*. British Journal of Dermatology, 2021, 185, 412-418.	1.4	14
736	High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. European Journal of Cancer, 2021, 149, 105-113.	1.3	4
737	Hidden in plain sight. Melanoma Research, 2021, Publish Ahead of Print, 389-392.	0.6	0
738	Histopathologic synoptic reporting of invasive melanoma: How reliable are the data?. Cancer, 2021, 127, 3125-3136.	2.0	5
739	The role of osteopontin in the development and metastasis of melanoma. Melanoma Research, 2021, 31, 283-289.	0.6	6
740	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. European Journal of Cancer, 2021, 148, 51-57.	1.3	16
741	PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review. Melanoma Research, 2021, 31, 397-401.	0.6	4
742	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. Frontiers in Oncology, 2021, 11, 672172.	1.3	2
743	Neoadjuvant Therapy in Resectable Melanoma. Advances in Oncology, 2021, 1, 41-48.	0.1	0
744	Malignant Tumours Presenting as Chronic Leg or Foot Ulcers. Journal of Clinical Medicine, 2021, 10, 2251.	1.0	4
745	The Role of Clinical Prediction Tools to Risk Stratify Patients with Melanoma After a Positive Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2021, 28, 4082-4083.	0.7	4
746	Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Research, 2021, 31, 449-455.	0.6	9
747	The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies. Melanoma Research, 2021, Publish Ahead of Print, 290-297.	0.6	2
748	Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance. JAMA Dermatology, 2021, 157, 521.	2.0	25
749	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	1.3	15

#	ARTICLE	IF	CITATIONS
750	Current Status and Prospects of Immunotherapy for Gynecologic Melanoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 403.	1.1	4
751	Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. <i>Cancers</i> , 2021, 13, 2319.	1.7	15
752	Survival models induced by zero-modified power series discrete frailty: Application with a melanoma data set. <i>Statistical Methods in Medical Research</i> , 2021, 30, 1874-1889.	0.7	1
753	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	5.1	224
754	The Negative Binomial Beta Prime Regression Model with Cure Rate: Application with a Melanoma Dataset. <i>Journal of Statistical Theory and Practice</i> , 2021, 15, 1.	0.3	4
755	Mucosal Melanomas of the Anogenital Tract. <i>Surgical Pathology Clinics</i> , 2021, 14, 225-235.	0.7	0
756	Obesity is not associated with disease-free interval, melanoma-specific survival, or overall survival in patients with clinical stage IB melanoma after SLNB. <i>Journal of Surgical Oncology</i> , 2021, 124, 655-664.	0.8	3
757	Identifying High-Risk Tumors within AJCC Stage IB melanomas Using a Seven-Marker Immunohistochemical Signature. <i>Cancers</i> , 2021, 13, 2902.	1.7	6
758	Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. <i>Gynecologic Oncology</i> , 2021, 161, 645-652.	0.6	15
759	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	13.9	201
760	Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment. <i>Immunotherapy</i> , 2021, 13, 653-659.	1.0	13
761	Vulvar and Vaginal Melanomas—The Darker Shades of Gynecological Cancers. <i>Biomedicines</i> , 2021, 9, 758.	1.4	10
762	Functional assessment of cancer therapy questionnaire for melanoma in the Serbian population: A factor analytic approach. <i>PLoS ONE</i> , 2021, 16, e0253937.	1.1	1
763	Re-thinking therapeutic development for CNS metastatic disease. <i>Experimental Dermatology</i> , 2021, , .	1.4	1
764	Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. <i>Cancers</i> , 2021, 13, 2875.	1.7	14
765	Head & neck melanoma: A 22-year experience of recurrence following sentinel lymph node biopsy. <i>Laryngoscope Investigative Otolaryngology</i> , 2021, 6, 738-746.	0.6	1
766	Multidisciplinary Care of BRAF-Mutant Stage III Melanoma: A Physicians Perspective Review. <i>Oncologist</i> , 2021, 26, e1644-e1651.	1.9	5
768	The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma. <i>Modern Pathology</i> , 2021, 34, 1839-1849.	2.9	13

#	ARTICLE	IF	CITATIONS
769	How we treat locoregional melanoma. <i>ESMO Open</i> , 2021, 6, 100136.	2.0	10
770	Impact of multiple lymphatic basin drainage in truncal melanoma patients. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, 75, 217-225.	0.5	0
771	Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. <i>Future Oncology</i> , 2021, 17, 2151-2167.	1.1	4
772	Association of the Affordable Care Act's Medicaid expansion with the diagnosis and treatment of clinically localized melanoma: A National Cancer Database study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1628-1635.	0.6	9
773	Trend Shifts in Age-Specific Incidence for In Situ and Invasive Cutaneous Melanoma in Sweden. <i>Cancers</i> , 2021, 13, 2838.	1.7	10
774	Non-invasive optical methods for melanoma diagnosis. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 34, 102266.	1.3	17
775	Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. <i>Nature Communications</i> , 2021, 12, 4031.	5.8	21
776	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 670726.	1.3	26
777	Targeted screening for melanoma after a 5-year follow-up: Comparison of melanoma incidence and lesion thickness at diagnosis in screened (versus unscreened) patients. <i>La Presse Médicale Open</i> , 2021, 2, 100013.	0.1	0
778	Inconsistencies in Cutaneous Melanoma Staging Within SEER Registries. <i>JAMA Dermatology</i> , 2021, 157, 727.	2.0	6
779	Health utilities for non-melanoma skin cancers and pre-cancerous lesions: A systematic review. <i>Skin Health and Disease</i> , 2021, 1, e51.	0.7	5
780	Microbeam Radiotherapy—A Novel Therapeutic Approach to Overcome Radioresistance and Enhance Anti-Tumour Response in Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7755.	1.8	18
781	Nodular melanoma on lip with retrograde in-transit metastases on face. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 87, 687-689.	0.2	0
782	Surgical excision margins in primary cutaneous melanoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1558-1574.	0.5	7
783	Oral Amelanotic Melanoma: A Systematic Review of Case Reports and Case Series. <i>Head and Neck Pathology</i> , 2022, 16, 513-524.	1.3	4
784	Surgical procedures in melanoma: recommended deep and lateral margins, indications for sentinel lymph node biopsy, and complete lymph node dissection. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.1	3
785	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. <i>European Journal of Cancer</i> , 2021, 152, 139-154.	1.3	13
786	Identification of Potential Prognostic Biomarkers Associated With Cancer Metastasis in Skin Cutaneous Melanoma. <i>Frontiers in Genetics</i> , 2021, 12, 687979.	1.1	5

#	ARTICLE	IF	CITATIONS
787	Novel adjuvant options for cutaneous melanoma. <i>Annals of Oncology</i> , 2021, 32, 854-865.	0.6	31
788	Sentinel lymph node biopsy versus elective neck dissection in squamous cell carcinoma of the oral cavity with a clinically <scp>N0</scp> neck: Systematic review and meta-analysis of prospective studies. <i>Head and Neck</i> , 2021, 43, 3185-3198.	0.9	17
789	Optimizing Detection of Lymphatic Invasion in Primary Cutaneous Melanoma With the Use of D2-40 and a Paired Melanocytic Marker. <i>American Journal of Dermatopathology</i> , 2022, 44, 21-27.	0.3	4
790	Melanoma: Staging and Follow-Up. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021162S.	0.5	6
791	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021165S.	0.5	0
792	Histopathologic classification and prognostic factors of melanoma: a 2021 update. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 300-321.	0.1	30
793	AP-2 $\beta$ -Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis. <i>Cancer Research</i> , 2021, 81, 4455-4470.	0.4	15
794	Comparative performance of predictors of death from thin ( $\leq$ 1.0 mm) melanoma. <i>British Journal of Dermatology</i> , 2021, 185, 849-851.	1.4	3
795	An Integrated Microfluidic $\mu$ SERS Platform Enables Sensitive Phenotyping of Serum Extracellular Vesicles in Early Stage Melanomas. <i>Advanced Functional Materials</i> , 2022, 32, 2010296.	7.8	30
796	Early melanoma invasivity correlates with gut fungal and bacterial profiles. <i>British Journal of Dermatology</i> , 2022, 186, 106-116.	1.4	26
797	Not all melanomas are created equal: a review and call for more research into nodular melanoma. <i>British Journal of Dermatology</i> , 2021, 185, 700-710.	1.4	12
798	Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist. <i>Annals of Translational Medicine</i> , 2021, 9, 1172-1172.	0.7	0
799	Molecular characterization of fast-growing melanomas. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 312-321.	0.6	11
800	Recognition, Staging, and Management of Melanoma. <i>Medical Clinics of North America</i> , 2021, 105, 643-661.	1.1	4
801	Adjuvant anti $\text{PD-1}$ antibody treatment in stage $\text{III/IV}$ melanoma: real-world experience and health economic considerations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1186-1198.	0.4	3
802	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. <i>ANZ Journal of Surgery</i> , 2021, 91, 3-13.	0.3	7
803	Larger Tumors Are Associated with Poorer Prognostic Factors in Cutaneous Melanoma. <i>Indian Journal of Surgery</i> , 0, , 1.	0.2	0
804	Genetic markers for characterization and prediction of prognosis of melanoma subtypes: a 2021 update. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 322-330.	0.1	4

#	ARTICLE	IF	CITATIONS
805	Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 702287.	1.3	31
806	Treatment of Advanced Metastatic Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021164S.	0.5	10
807	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. <i>Current Problems in Surgery</i> , 2022, 59, 101030.	0.6	4
808	Clinicopathologic Characteristics and Prognostic Factors Impacting Survival in Melanoma of the Eyelid. <i>American Journal of Ophthalmology</i> , 2021, 234, 71-80.	1.7	1
809	Specialised skin cancer spectral library for use in data-independent mass spectrometry. <i>Proteomics</i> , 2021, 21, e2100128.	1.3	3
810	Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease. <i>JAMA Oncology</i> , 2021, 7, 1220.	3.4	5
811	Need to restage Korean melanoma patients following publication of the 8th edition of the American Joint Committee on Cancer staging manual. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, .	0.2	0
812	Clinicopathological features and associations in a series of South African acral melanomas. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 1120-1122.	1.5	2
814	Genetic variants of SDCCAG8 and MAGI2 in mitosis-related pathway genes are independent predictors of cutaneous melanoma-specific survival. <i>Cancer Science</i> , 2021, 112, 4355-4364.	1.7	1
815	Recurrence of Thin Cutaneous Melanoma in the Optic Nerve After Over a Decade of Clinical Cure. <i>Journal of Neuro-Ophthalmology</i> , 2022, 42, e343-e346.	0.4	0
816	Stem cell spreading dynamics intrinsically differentiate acral melanomas from nevi. <i>Cell Reports</i> , 2021, 36, 109492.	2.9	8
817	The impact of incomplete clinical information and initial biopsy technique on the histopathological diagnosis of cutaneous melanoma. <i>Australasian Journal of Dermatology</i> , 2021, 62, e524-e531.	0.4	6
818	Cells to Surgery Quiz: August 2021. <i>Journal of Investigative Dermatology</i> , 2021, 141, e93-e101.	0.3	0
819	Residual melanoma in wide local excision specimens after "complete" excision of primary cutaneous in situ and invasive melanomas. <i>Pathology</i> , 2022, 54, 71-78.	0.3	2
820	Broad-Spectrum Antibiotic Use and Disease Progression in Early-Stage Melanoma Patients: A Retrospective Cohort Study. <i>Cancers</i> , 2021, 13, 4367.	1.7	2
821	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
822	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913.	1.7	5
823	Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial. <i>Genetics in Medicine</i> , 2021, 23, 2394-2403.	1.1	22

#	ARTICLE	IF	CITATIONS
824	A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era. <i>Journal of Surgical Oncology</i> , 2021, 124, 1544-1550.	0.8	4
825	Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction. <i>JCO Precision Oncology</i> , 2021, 5, 1466-1479.	1.5	17
826	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2028-2036.e2.	0.3	17
827	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , 2021, 73, 101943.	0.8	21
828	Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision. <i>Biomarkers in Medicine</i> , 2021, 15, 1111-1122.	0.6	4
829	Prognosis in Thin Melanoma Patients: Is Slightly Less Than Excellent Still Okay?. <i>Annals of Surgical Oncology</i> , 2021, 28, 6911-6914.	0.7	0
830	BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma. <i>Radiation Oncology</i> , 2021, 16, 181.	1.2	5
831	Application of an indocyanine green surgical fluorescence imaging system in sentinel lymph node biopsy of acral malignant melanoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1456-1456.	0.7	1
832	Non-Sentinel Lymph Node Detection during Sentinel Lymph Node Biopsy in Not-Complete-Lymph-Node-Dissection Era: A New Technique for Better Staging and Treating Melanoma Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 4319.	1.0	2
833	The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. <i>Targeted Oncology</i> , 2021, 16, 537-552.	1.7	20
834	Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma. <i>JAMA Surgery</i> , 2021, 156, e214298.	2.2	1
835	Emerging Minimally Invasive Technologies for the Detection of Skin Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 951.	1.1	8
836	The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma. <i>Future Oncology</i> , 2021, 17, 5023-5031.	1.1	6
837	Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10568.	1.8	0
838	Outcome of pretransplant melanoma after solid organ transplantation: an observational study. <i>Transplant International</i> , 2021, 34, 2154-2165.	0.8	0
839	Adjuvant treatment for melanoma in clinical practice – Trial versus reality. <i>European Journal of Cancer</i> , 2021, 158, 234-245.	1.3	12
840	Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases. <i>Melanoma Research</i> , 2021, 31, 575-578.	0.6	5
841	Loss of miR-1469 expression mediates melanoma cell migration and invasion. <i>PLoS ONE</i> , 2021, 16, e0256629.	1.1	2

#	ARTICLE	IF	CITATIONS
842	Demographic, clinical and morphological profile of malignant cutaneous melanoma in a Northeastern region of Bulgaria. <i>Scripta Scientifica Medica</i> , 2021, 53, 21.	0.1	0
843	Employing competing risks analysis in an aging population where many patients die from other causes. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	0
844	Impact of the changes in the completion lymph node dissection criteria and approval of adjuvant therapies on the real-world outcomes of Japanese stage III melanoma patients. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2338-2346.	1.0	3
845	On a new piecewise regression model with cure rate: Diagnostics and application to medical data. <i>Statistics in Medicine</i> , 2021, 40, 6723-6742.	0.8	9
846	Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers. <i>Cancers</i> , 2021, 13, 4943.	1.7	37
847	COVID-19-Induced Reduction in Primary Melanoma Diagnoses: Experience from a Dermatopathology Referral Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 4059.	1.0	13
848	Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. <i>BMC Cancer</i> , 2021, 21, 1014.	1.1	3
849	Histopathologic and Molecular Diagnosis of Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 587-598.	0.7	6
850	Sentinel Lymph Node Biopsy, Lymph Node Dissection, and Lymphedema Management Options in Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 607-616.	0.7	2
851	Extirpative Considerations of Melanoma of the Head and Neck. <i>Clinics in Plastic Surgery</i> , 2021, 48, 659-668.	0.7	3
852	Thoracic metastasis of malignant melanoma of unknown primary: A case report and literature review. <i>International Journal of Surgery Case Reports</i> , 2021, 87, 106383.	0.2	0
853	Non-Operative Options for Loco-regional Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 631-642.	0.7	1
854	American Joint Committee on Cancer Staging and Other Platforms to Assess Prognosis and Risk. <i>Clinics in Plastic Surgery</i> , 2021, 48, 599-606.	0.7	6
855	Predictive Factors for Metastasis of Skin Melanoma of Varying Thickness According to Breslow to Sentinel Lymph Nodes. <i>Journal of Oncology Diagnostic Radiology and Radiotherapy</i> , 2021, 4, 18-25.	0.1	0
856	Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study. <i>European Journal of Cancer</i> , 2021, 157, 361-372.	1.3	24
857	Galactofucoidans from <i>Sargassum fusiforme</i> and their antagonistic effects against the proliferation-inhibition of RAW264.7 macrophage induced by culture supernatants of melanoma cells. <i>Carbohydrate Polymer Technologies and Applications</i> , 2021, 2, 100090.	1.6	2
858	Early stage melanoma diagnosis and mental health-related: emotional influence of body self-perception. <i>Journal of Affective Disorders Reports</i> , 2021, 6, 100188.	0.9	1
860	Sex-specific survival benefit in early skin melanoma based on 8th AJCC edition: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database. <i>Annals of Translational Medicine</i> , 2021, 9, 53-53.	0.7	3



#	ARTICLE	IF	CITATIONS
861	Differences Between Recommended Surgical Margins and Measured Histological Margins in Malignant Melanoma In Situ and Malignant Melanomas. American Journal of Dermatopathology, 2021, Publish Ahead of Print, 881-886.	0.3	4
862	Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma. Oncoimmunology, 2021, 10, 1901446.	2.1	2
863	Survival and Prognostic Nomogram for Primary Gastrointestinal Melanoma (PGIM): A Population-based Study. Anticancer Research, 2021, 41, 967-974.	0.5	5
864	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. Expert Review of Precision Medicine and Drug Development, 2021, 6, 19-29.	0.4	3
865	Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults. The Cochrane Library, 2018, 2018, CD013186.	1.5	65
866	Isolated Limb Infusion for Melanoma. , 2020, , 827-850.		1
867	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. , 2020, , 867-894.		3
868	Classification and Histopathology of Melanoma. , 2020, , 317-379.		1
869	Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 767-793.		1
870	Preoperative and Intraoperative Lymphatic Mapping for Radioguided Sentinel Lymph Node Biopsy in Cutaneous Melanoma. , 2020, , 219-259.		4
871	Mucosal Melanoma. , 2019, , 1-17.		1
872	The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World. American Journal of Clinical Dermatology, 2021, 22, 233-242.	3.3	26
873	Sentinel Lymph Node Biopsy. Surgical Oncology Clinics of North America, 2020, 29, 401-414.	0.6	3
874	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Review of Anticancer Therapy, 2018, 18, 775-784.	1.1	268
875	Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.. Japanese Journal of Clinical Oncology, 2021, 51, 192-198.	0.6	9
876	Subtyping Cutaneous Melanoma Matters. JNCI Cancer Spectrum, 2020, 4, pkaa097.	1.4	17
877	Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma. Melanoma Research, 2019, 29, 648-654.	0.6	8
878	Identification of prognostic mRNAs in metastatic cutaneous melanoma. Melanoma Research, 2020, 30, 543-547.	0.6	7

#	ARTICLE	IF	CITATIONS
879	MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas. <i>Melanoma Research</i> , 2021, 31, 18-26.	0.6	5
880	Molecular Alterations in Vaginal Melanomas: Report of 4 Cases and Literature Review. <i>American Journal of Dermatopathology</i> , 2021, 43, 45-48.	0.3	2
884	Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. , 2020, 8, e001607.		4
885	218â€...A preclinical study of IMC-002, a fully human therapeutic antibody safely targeting CD47 in cancer. , 2020, , .		1
886	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 1886-1895.	3.2	42
887	Timed Ang2-Targeted Therapy Identifies the Angiopoietinâ€Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis. <i>Cancer Discovery</i> , 2021, 11, 424-445.	7.7	18
888	Acetylsalicylic Acid Exerts Potent Antitumor and Antiangiogenic Effects in Cutaneous and Uveal Melanoma Cell Lines. <i>Ocular Oncology and Pathology</i> , 2020, 6, 442-455.	0.5	3
889	H3K27me3-mediated PGC1± gene silencing promotes melanoma invasion through WNT5A and YAP. <i>Journal of Clinical Investigation</i> , 2020, 130, 853-862.	3.9	32
890	Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 5128-5136.	0.7	13
891	Performance Improvement of Automated Melanoma Diagnosis System by Data Augmentation. <i>Advanced Biomedical Engineering</i> , 2020, 9, 62-70.	0.4	4
892	The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. <i>Oncotarget</i> , 2018, 9, 26217-26225.	0.8	6
893	Tumor tissue hnRNP M and HSP 90± as potential predictors of disease-specific mortality in patients with early-stage cutaneous head and neck melanoma: A proteomics-based study. <i>Oncotarget</i> , 2019, 10, 6713-6722.	0.8	4
894	The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab. <i>Annals of Translational Medicine</i> , 2019, 7, S24-S24.	0.7	8
895	&lt;p&gt;Long Noncoding RNA &lt;em&gt;LINC00173&lt;/em&gt; Promotes the Malignancy of Melanoma by Promoting the Expression of IRS4 Through Competitive Binding to microRNA-493&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 3131-3144.	0.9	13
896	Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 2792-2813.	1.2	12
897	Malignant Cutaneous Melanoma: Updates in PET Imaging. <i>Current Radiopharmaceuticals</i> , 2020, 13, 14-23.	0.3	7
898	Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases. <i>Acta Dermato-Venereologica</i> , 2020, 100, 1-8.	0.6	13
899	Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00083-9.	0.6	17

#	ARTICLE	IF	CITATIONS
900	Lentigo maligna: diagnosis and treatment. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 179-189.	0.8	2
901	Management of cutaneous melanoma: comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 126-145.	0.8	5
902	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 162-174.	0.4	38
903	Anorectal Melanoma - a Histopathological Case Report and a Review of the Literature. <i>Folia Medica</i> , 2018, 60, 641-646.	0.2	7
904	Retrospective analysis of treatment-naïve Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience. <i>Radiology and Oncology</i> , 2020, 54, 119-127.	0.6	8
905	Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma. <i>SKIN the Journal of Cutaneous Medicine</i> , 2019, 3, 239-249.	0.1	5
906	Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e94.	1.0	29
907	Long non-coding RNAs lncANGPTL1 <sup>3:3</sup> and lncGJA10 <sup>12:1</sup> present as regulators of sentinel lymph node metastasis in breast cancer. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	10
908	Long non-coding RNA SNHG6 promotes tumorigenesis in melanoma cells via the microRNA <sup>101</sup> <sup>3p</sup> /RAP2B axis. <i>Oncology Letters</i> , 2020, 20, 323.	0.8	6
909	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326
910	NCCN Guidelines <sup>®</sup> Insights: Melanoma: Cutaneous, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 364-376.	2.3	167
911	A spindle cell squamous cell carcinoma on the cheek presenting with in-transit metastases and a satellite lesion. <i>Archives of Craniofacial Surgery</i> , 2020, 21, 58-63.	0.4	3
912	A machine learning approach to automatic detection of irregularity in skin lesion border using dermoscopic images. <i>PeerJ Computer Science</i> , 2020, 6, e268.	2.7	33
913	Cutaneous Melanoma and Other Skin Cancers. <i>UNIPA Springer Series</i> , 2021, , 979-1007.	0.1	0
914	Survival in Patients With Sentinel Node-Positive Melanoma With Extranodal Extension. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1165-1173.	2.3	3
915	Association between melanoma thickness and clinical and demographic characteristics. <i>European Journal of Dermatology</i> , 2021, 31, 514-520.	0.3	3
916	Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma. <i>Aging</i> , 2021, 13, 23036-23071.	1.4	3
917	UBTF facilitates melanoma progression via modulating MEK1/2-ERK1/2 signalling pathways by promoting GIT1 transcription. <i>Cancer Cell International</i> , 2021, 21, 543.	1.8	9

#	ARTICLE	IF	CITATIONS
918	A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma. <i>Acta Oncologica</i> , 2022, 61, 14-21.	0.8	1
919	Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma. <i>International Journal of Dermatology</i> , 2022, 61, 472-479.	0.5	6
920	BRAFV600E Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics. <i>Cancers</i> , 2021, 13, 5073.	1.7	2
921	Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy Staging of Primary Cutaneous Melanoma and Patient Outcomes. <i>Annals of Surgical Oncology</i> , 2022, 29, 767-775.	0.7	9
922	Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma. <i>Molecules</i> , 2021, 26, 6003.	1.7	7
923	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 2021, 9, e002995.		18
924	Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma. <i>Clinical and Translational Medicine</i> , 2021, 11, e608.	1.7	8
925	Clioblastoma and malignant melanoma: Serendipitous or anticipated association?. <i>Neuropathology</i> , 2021, 41, 489-491.	0.7	2
928	A novel pyroptosis-associated gene signature for immune status and prognosis of cutaneous melanoma. <i>PeerJ</i> , 2021, 9, e12304.	0.9	14
929	More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population-based study of 7148 patients. <i>Journal of Surgical Oncology</i> , 2022, 125, 498-508.	0.8	8
930	High-Plex Spatial RNA Profiling Reveals Cell Type-Specific Biomarker Expression during Melanoma Development. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1401-1412.e20.	0.3	10
931	Risk factors of recurrence and distant metastasis in primary cutaneous melanoma in Taiwan. <i>Scientific Reports</i> , 2021, 11, 21012.	1.6	6
932	Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. <i>European Journal of Cancer</i> , 2021, 158, 72-84.	1.3	14
933	Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study. <i>JAAD International</i> , 2021, 5, 112-120.	1.1	10
934	Melanoma Clinical Staging (Historical and Current). , 2018, , 1-16.		0
935	Cutaneous melanoma. <i>Journal of the Korean Medical Association</i> , 2018, 61, 662.	0.1	0
936	Cardiac metastasis of malignant melanoma: where are we standing?. , 2018, 01, .		0
937	Malignes Melanom: Optionen für Patienten im fortgeschrittenen Stadium. <i>Deutsches Arzteblatt International</i> , 0, , .	0.6	0

#	ARTICLE	IF	CITATIONS
938	Melanoma Prevention and Screening. , 2019, , 1-46.		1
939	Isolated Limb Infusion for Melanoma. , 2019, , 1-24.		0
940	Evolving Role of the Oncology Nurse in the Care of Patients with Melanoma. , 2019, , 1-27.		1
941	Genomic Applications in Melanoma. , 2019, , 509-540.		0
942	Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-27.		0
943	Classification and Histopathology of Melanoma. , 2019, , 1-64.		0
944	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
945	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-20.		0
946	Biomarkers for Melanoma. , 2019, , 1-32.		0
947	Diagnosis of Stage IV Melanoma. , 2019, , 1-47.		1
948	Melanom. , 2019, , 45-134.		0
949	Models for Predicting Melanoma Outcome. , 2019, , 1-16.		0
950	Hauttumoren. , 2019, , 285-291.		0
952	Melanom. , 2019, , 89-102.		0
953	Melanoma Prognosis and Staging. , 2019, , 1-27.		0
954	Current Treatment Strategies in Cutaneous Malignant Melanoma of the Head and Neck. Ent Updates, 0, , .	0.0	0
955	Sentinel Lymph Node Biopsy in Head and Neck Cutaneous Malignant Melanoma. Journal of the Portuguese Society of Dermatology and Venereology, 2019, 77, 129-133.	0.0	0
956	Combined Immunotherapy in Metastatic Melanoma with Unknown Primary. Cureus, 2019, 11, e5324.	0.2	1

#	ARTICLE	IF	CITATIONS
959	Malignancy, Staging and Surgical Management. , 2020, , 77-104.		0
960	Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.		0
961	Treatment of Occupational Skin Cancer. , 2020, , 1483-1492.		0
962	Clinical characteristics of malignant melanoma in central China and predictors of metastasis. <i>Oncology Letters</i> , 2020, 19, 1452-1464.	0.8	5
963	Models for Predicting Melanoma Outcome. , 2020, , 299-314.		0
964	Fluorescent Lymphangiography: Sentinel Node Navigation Surgery in Melanoma. , 2020, , 273-280.		0
966	Melanoma Prevention and Screening. , 2020, , 525-570.		4
967	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 747-766.		0
970	Surgery for Stage IV Melanoma. , 2021, , 171-189.		0
971	Melanoma Epidemiology, Staging and Prognostic Factors. , 2021, , 61-81.		0
973	Regional Melanoma Therapy: Positive Sentinel Lymph Node. , 2021, , 149-160.		0
974	Regional Nodal Staging: Clinically Node Negative. , 2021, , 125-147.		0
975	Patient with metastatic malignant melanoma treated with pembrolizumab. <i>Onkologie (Czech Republic)</i> , 2020, 14, 44-46.	0.0	0
976	Delivering Clinical Skin Examination Education to Nurse Practitioners Using an Internet-Based, Microlearning Approach: Development and Feasibility of a Video Intervention. <i>JMIR Dermatology</i> , 2020, 3, e16714.	0.4	1
977	Current prospects of successful therapeutic procedures in advanced stage melanoma – the short review. <i>Journal of Education, Health and Sport</i> , 2020, 10, 308.	0.0	0
978	Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients. <i>Aging</i> , 2020, 12, 16457-16475.	1.4	2
980	Surgical Reconstruction following Wide Local Excision of Malignant Melanoma of the Scalp. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2020, 8, e3059.	0.3	0
981	Features associated with melanoma metastasis in Latvia. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	0

#	ARTICLE	IF	CITATIONS
982	Tratamiento adyuvante de melanoma cutáneo : indicaciones y alternativas.. Revista Colombiana De Hematología Y Oncología, 2020, 7, 56-63.	0.0	0
984	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma. Journal of Clinical Medicine, 2021, 10, 4994.	1.0	4
985	A disease network-based deep learning approach for characterizing melanoma. International Journal of Cancer, 2022, 150, 1029-1044.	2.3	16
986	Bioinformatic and Machine Learning Applications in Melanoma Risk Assessment and Prognosis: A Literature Review. Genes, 2021, 12, 1751.	1.0	7
987	Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy. Thoracic Cancer, 2021, 12, 3101-3109.	0.8	11
988	Mucosal Melanoma. , 2020, , 953-968.		0
990	Multiscale Dilated UNet for Segmentation of Multi-Organ Nuclei in Digital Histology Images. , 2020, , .		6
991	The Role of PET/CT in Melanoma Patients: A Surgeon's Perspective. , 2021, , 151-166.		0
993	Letter Regarding Editorial by Samuel Zagarella. American Journal of Dermatopathology, 2021, 43, 539-541.	0.3	2
994	Huidtumoren. , 2020, , 411-431.		0
995	Cutaneous Melanoma – A Review of Systemic Therapies. Acta Dermato-Venereologica, 2020, 100, adv00141.	0.6	7
996	Diagnosis of Stage IV Melanoma. , 2020, , 997-1043.		0
998	Cancer stem cells, plasticity, and drug resistance. , 2020, 3, 140-148.		0
999	Melanoma Prognosis and Staging. , 2020, , 271-297.		2
1000	Análisis de las modificaciones en la estadificación del T según el manual del American Joint Committee on Cancer. ¿Cómo cambia nuestro manejo de los pacientes?. Dermatología Argentina, 2020, 26, 23-25.	0.0	0
1001	Adjuvant therapy for melanoma: how to choose?. Lancet Oncology, The, 2020, 21, 319-320.	5.1	2
1003	Body Mass Index and Melanoma Prognosis. Dermatology Practical and Conceptual, 2021, 11, e2021106.	0.5	3
1004	Association Between Melanoma Detected During Routine Skin Checks and Mortality. JAMA Dermatology, 2021, 157, 1425.	2.0	27



#	ARTICLE	IF	CITATIONS
1005	<sup>18</sup> Fâ€FDG positron emission tomographyâ€computed tomographyâ€has a low positive predictive value for detecting occult recurrence in asymptomatic patients with highâ€risk Stages IIB, IIC, and IIIA melanoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 525-534.	0.8	0
1006	Non-invasive diagnostic techniques for skin tumors and their potential for use in skin melanoma screening: a systematic literature review. <i>Meditinskiy Sovet</i> , 2020, , 102-120.	0.1	1
1007	Approaches to metastatic skin melanoma therapy in 2020: a dynamic way forward. <i>Meditinskiy Sovet</i> , 2020, , 80-93.	0.1	0
1008	Is AJCC 8th Edition useful in qualifying melanoma patients to adjuvant therapy?. <i>Annals of Translational Medicine</i> , 2020, 8, 898-898.	0.7	0
1011	New Melanoma Staging: Prognostic Factors. <i>Updates in Surgery Series</i> , 2021, , 47-53.	0.0	0
1012	The Rationale of Sentinel Lymph Node Biopsy. <i>Updates in Surgery Series</i> , 2021, , 85-95.	0.0	0
1013	Does morphology have real impact on local and distant recurrences in head and neck cutaneous melanoma?. <i>Opuholi Golovy I Sei</i> , 2020, 10, 55-64.	0.1	0
1014	Sleep Duration and Cutaneous Melanoma Aggressiveness. A Prospective Observational Study in 443 Patients. <i>Archivos De Bronconeumologia</i> , 2021, 57, 776-778.	0.4	2
1015	Improving Reporting of Tumor Size in Synoptic Reports. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 969-972.	1.2	3
1016	Diagnosis of melanocytic neoplasms: a literature review. <i>Russian Journal of Skin and Venereal Diseases</i> , 2020, 23, 278-287.	0.0	0
1017	Melanoma Radiological Surveillance: A Review of Current Evidence and Clinical Challenges. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 207-213.	0.2	5
1018	Trend and socioeconomic disparities in survival outcome of metastatic melanoma after approval of immune checkpoint inhibitors: a population-based study. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3767-3779.	0.0	3
1019	Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management. <i>American Journal of Cancer Research</i> , 2020, 10, 4017-4037.	1.4	2
1020	The effect of the COVID-19 pandemic on skin cancer surgery in the United Kingdom: a national, multi-centre, prospective cohort study and survey of Plastic Surgeons. <i>British Journal of Surgery</i> , 2020, 107, e598-e600.	0.1	12
1021	Pelvic sentinel lymph nodes have minimal impact on survival in melanoma patients. <i>BJS Open</i> , 2021, 5, .	0.7	2
1022	Protein expression of prognostic genes in primary melanoma and benign nevi. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2673-2680.	1.2	4
1023	Characterization of the CpG Island Hypermethylated Phenotype Subclass in Primary Melanomas. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1869-1881.e10.	0.3	5
1024	External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	1

#	ARTICLE	IF	CITATIONS
1025	Nomogram based on autophagy related genes for predicting the survival in melanoma. BMC Cancer, 2021, 21, 1258.	1.1	6
1027	Oxidative Stress and Autophagy as Key Targets in Melanoma Cell Fate. Cancers, 2021, 13, 5791.	1.7	10
1028	Radiotherapy in the Treatment of Subcutaneous Melanoma. Cancers, 2021, 13, 5859.	1.7	5
1029	ASO Author Reflections: Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy Staging of Primary Cutaneous Melanoma and Patient Outcomes. Annals of Surgical Oncology, 2021, 29, 776.	0.7	3
1030	Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. European Journal of Surgical Oncology, 2022, 48, 320-325.	0.5	18
1031	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 2021, 158, 156-168.	1.3	19
1032	Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician. Cancers, 2021, 13, 5625.	1.7	8
1033	Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice. Cureus, 2021, 13, e19835.	0.2	0
1034	Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF). JAMA Dermatology, 2022, 158, 33.	2.0	26
1035	Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors. European Radiology, 2022, 32, 3398-3407.	2.3	8
1036	Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy. Cancers, 2021, 13, 6061.	1.7	5
1037	High-resolution three-dimensional imaging for precise staging in melanoma. European Journal of Cancer, 2021, 159, 182-193.	1.3	8
1038	Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data*. British Journal of Dermatology, 2022, 186, 835-842.	1.4	14
1039	Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. ESMO Open, 2021, 6, 100303.	2.0	7
1040	Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open, 2021, 6, 100325.	2.0	24
1041	Sleep Duration and Cutaneous Melanoma Aggressiveness. A Prospective Observational Study in 443 Patients. Archivos De Bronconeumologia, 2021, 57, 776-778.	0.4	1
1043	Evolution of Melanoma Staging. , 2021, , 139-153.		0
1044	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis. Cancer Control, 2021, 28, 107327482110535.	0.7	7

#	ARTICLE	IF	CITATIONS
1045	Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression. Tzu Chi Medical Journal, 2022, 34, 1.	0.4	8
1046	Sentinel lymph node localization and staging with a low-dose of superparamagnetic iron oxide (SPIO) enhanced MRI and magnetometer in patients with cutaneous melanoma of the extremity - The MAGMEN feasibility study. European Journal of Surgical Oncology, 2022, 48, 326-332.	0.5	9
1047	Surgical Outcomes of Vaginal or Cervical Melanoma. Frontiers in Surgery, 2021, 8, 771160.	0.6	1
1048	InÂVivo Melanoma Cell Morphology Reflects Molecular Signature and Tumor Aggressiveness. Journal of Investigative Dermatology, 2022, 142, 2205-2216.e6.	0.3	16
1049	Improving Skin cancer Management with ARTificial Intelligence (SMARTI): protocol for a preintervention/postintervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a specialist dermatology setting. BMJ Open, 2022, 12, e050203.	0.8	11
1050	High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine. BMC Cancer, 2022, 22, 29.	1.1	4
1051	Utilization and survival benefit of adjuvant immunotherapy in resected high-risk stage II melanoma. Surgery in Practice and Science, 2022, 8, 100056.	0.2	0
1052	Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma. International Journal of Molecular Sciences, 2022, 23, 1119.	1.8	10
1053	PIVOT-12: aÂPhase IIIÂstudy of adjuvant bempedalesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology, 2022, 18, 903-913.	1.1	7
1054	Seasonal variation in high-risk phenotypes of cutaneous malignant melanoma diagnosed in Eastern England: An observational study. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2022, 75, 1923-1930.	0.5	1
1055	Optimal Surveillance Strategies for Early-Stage Cutaneous Melanoma Post Primary Tumor Excision: An Economic Evaluation. MDM Policy and Practice, 2022, 7, 238146832110699.	0.5	0
1056	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	0.7	21
1057	Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study*. British Journal of Dermatology, 2022, 186, 977-987.	1.4	9
1058	TGFÎ² activating integrins Î²6 and Î²8 are dysregulated in inflammatory skin disease and cutaneous melanoma. Journal of Dermatological Science, 2022, 106, 2-11.	1.0	3
1059	The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma. Frontiers in Oncology, 2021, 11, 811434.	1.3	6
1060	Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. , 2022, 10, e004310.		6
1061	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	7.7	64
1062	The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. BMC Cancer, 2022, 22, 38.	1.1	4

#	ARTICLE	IF	CITATIONS
1063	Cost-Effectiveness of Pembrolizumab Versus Carboplatin and Paclitaxel in Patients With Unresectable or Metastatic Melanoma After First-Line Treatment in China. <i>Value in Health Regional Issues</i> , 2022, 27, 99-107.	0.5	3
1064	Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. <i>Current Medical Research and Opinion</i> , 2022, 38, 1267-1274.	0.9	8
1065	Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study. <i>International Journal of Dermatology</i> , 2022, , .	0.5	4
1066	Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma. <i>Endocrine Connections</i> , 2022, 11, .	0.8	4
1067	La fotografÃa corporal total estÃ cambiando el panorama diagnÃstico del melanoma cutÃneo. <i>Piel</i> , 2022, , .	0.0	0
1069	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 702.	1.7	3
1070	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (â¥15Åmm in thickness). <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 298-305.	0.6	3
1071	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.3	3
1072	Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival. <i>Gynecologic Oncology</i> , 2022, 165, 53-59.	0.6	1
1073	Circulating Tumour DNA in Melanomaâ€Clinic Ready?. <i>Current Oncology Reports</i> , 2022, 24, 363-373.	1.8	10
1074	Costâeffectiveness of a policyâbased intervention to reduce melanoma and other skin cancers associated with indoor tanning*. <i>British Journal of Dermatology</i> , 2022, 187, 105-114.	1.4	12
1075	Extra-Axial Skeletal Metastasis of Malignant Melanoma: Case Report and Literature Review. <i>Cureus</i> , 2022, 14, e22115.	0.2	0
1076	Melanoma and intellectual disability: do prognostic factors at diagnosis differ from general population?. <i>Journal of Intellectual Disability Research</i> , 2022, , .	1.2	0
1077	Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>European Journal of Surgical Oncology</i> , 2022, 48, 1280-1287.	0.5	7
1078	Managing Metastatic Melanoma in 2022: A Clinical Review. <i>JCO Oncology Practice</i> , 2022, 18, 335-351.	1.4	91
1079	Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, 98-102.	0.6	0
1080	The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2342-2351.	3.3	6
1081	The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 2871-2881.	0.7	5

#	ARTICLE	IF	CITATIONS
1082	Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma. <i>Annals of Diagnostic Pathology</i> , 2022, 58, 151909.	0.6	1
1083	Melanoma and Quality of Life. , 2022, , 439-466.		2
1088	25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions. <i>Current Oncology Reports</i> , 2022, 24, 533-542.	1.8	3
1089	Management of In-Transit Metastases. <i>Current Oncology Reports</i> , 2022, 24, 573.	1.8	0
1090	The prognosis of cutaneous malignant melanoma associated with paraneoplastic dermatomyositis. <i>International Journal of Dermatology</i> , 2022, , .	0.5	0
1091	Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study). <i>Cancers</i> , 2022, 14, 1040.	1.7	2
1092	Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma. <i>Journal of the American College of Surgeons</i> , 2022, 234, 521-528.	0.2	3
1093	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. <i>European Journal of Cancer</i> , 2022, 167, 133-141.	1.3	3
1094	Using a 31-Gene Expression Profile Test to Stratify Patients with Stage Iâ€“II Cutaneous Melanoma According to Recurrence Risk: Update to a Prospective, Multicenter Study. <i>Cancers</i> , 2022, 14, 1060.	1.7	3
1095	Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. <i>Medical Journal of Australia</i> , 2022, 217, 208-209.	0.8	3
1096	Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group. <i>Dermatology and Therapy</i> , 2022, 12, 807-823.	1.4	11
1097	Differences in Thickness-Specific Incidence and Factors Associated With Cutaneous Melanoma in the US From 2010 to 2018. <i>JAMA Oncology</i> , 2022, 8, 755.	3.4	20
1098	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. <i>Pathology</i> , 2022, , .	0.3	1
1099	The impact of the COVIDâ€™19 pandemic on melanoma diagnoses. , 2022, 1, 122-125.		1
1100	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.4	21
1101	F-18 Fluoro-2-Deoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Melanoma: Normal Variants, Pitfalls, and Artifacts. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	0.7	1
1102	The Interplay between Tumour Microenvironment Components in Malignant Melanoma. <i>Medicina (Lithuania)</i> , 2022, 58, 365.	0.8	8
1103	Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3178.	1.2	22

#	ARTICLE	IF	CITATIONS
1104	Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma. <i>British Journal of Cancer</i> , 2022, 126, 1450-1456.	2.9	0
1105	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. <i>European Journal of Cancer</i> , 2022, 167, 123-132.	1.3	4
1106	The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma. <i>Pathology Research and Practice</i> , 2022, , 153805.	1.0	1
1107	Comparison of the prognostic value of microscopically measured invasive width versus macroscopic width in cutaneous melanoma shows the superiority of microscopic invasive width measurement. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 536-542.	0.7	5
1108	Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 342-353.	0.5	0
1109	Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents. <i>Oncologist</i> , 2022, 27, 352-362.	1.9	6
1111	The Prognostic Value of miR-125b, miR-200c and miR-205 in Primary Cutaneous Malignant Melanoma Is Independent of BRAF Mutational Status. <i>Cancers</i> , 2022, 14, 1532.	1.7	1
1112	Impact of Reflex Testing for <i>BRAF</i> Mutational Status in Advanced Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, , .	1.2	0
1113	Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus. <i>Clinical and Translational Oncology</i> , 2022, , 1.	1.2	2
1114	Comments on Post-Publication Discussion of "Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma". <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
1115	Impact of a personal history of cutaneous squamous cell carcinoma in the overall survival of cutaneous melanoma patients. , 0, , .		0
1116	Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study. <i>PLoS ONE</i> , 2022, 17, e0265048.	1.1	2
1117	Retrospective analysis of secondary enucleation for uveal melanoma after plaque radiotherapy. <i>BMC Ophthalmology</i> , 2022, 22, 163.	0.6	2
1118	Diagnostic pitfalls after COVID-19 vaccination in melanoma and breast cancer patients: A case series. <i>International Journal of Surgery Case Reports</i> , 2022, 93, 106938.	0.2	1
1119	Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. <i>BioDrugs</i> , 2022, 36, 373-380.	2.2	2
1120	Predictors of Nodal Metastasis in Cutaneous Head and Neck Cancers. <i>Current Oncology Reports</i> , 2022, 24, 1145-1152.	1.8	5
1121	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	6.3	236
1122	Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease. <i>European Journal of Cancer</i> , 2022, 166, 240-253.	1.3	11



#	ARTICLE	IF	CITATIONS
1123	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. <i>European Journal of Cancer</i> , 2022, 167, 70-80.	1.3	19
1124	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10
1125	BIOIMPEDANCE ANALYSIS IN THE DIAGNOSIS OF SKIN CONDITION. <i>Bulletin of Kyiv Polytechnic Institute Series Instrument Making</i> , 2021, , 82-87.	0.0	0
1126	Primary deâ€differentiated, transâ€differentiated and undifferentiated melanomas: overview of the clinicopathological, immunohistochemical and molecular spectrum. <i>Histopathology</i> , 2022, 80, 135-149.	1.6	14
1127	Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma. <i>Cancers</i> , 2022, 14, 110.	1.7	5
1128	Sentinel Lymph Node Biopsy vs. Observation in Thin Melanoma: A Multicenter Propensity Score Matching Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5878.	1.0	2
1129	Multispectral Imaging Algorithm Predicts Breslow Thickness of Melanoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 189.	1.0	4
1130	Dermoscopy of Small Diameter Melanomas with the Diagnostic Feasibility of Selected Algorithmsâ€”A Clinical Retrospective Multicenter Study. <i>Cancers</i> , 2021, 13, 6095.	1.7	4
1131	Difficulties in diagnosing anorectal melanoma: A case report and review of the literature. <i>World Journal of Clinical Cases</i> , 2021, 9, 11369-11381.	0.3	1
1132	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. <i>Cancers</i> , 2021, 13, 6141.	1.7	11
1133	Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 772165.	1.3	10
1134	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Frontiers in Oncology</i> , 2022, 12, 820510.	1.3	2
1135	Current Trends in Circulating Biomarkers for Melanoma Detection. <i>Frontiers in Medicine</i> , 2022, 9, 873728.	1.2	11
1137	The future is hard to predict, even for patients with cutaneous squamous cell carcinoma. <i>British Journal of Dermatology</i> , 2022, , .	1.4	0
1138	ASO Author Reflections: Staging System for Mucosal Melanoma: A Proposal to Fill a Gap. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
1139	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow up? Statistical analysis plan for the MEL-SELF randomised controlled trial.. <i>Contemporary Clinical Trials</i> , 2022, , 106761.	0.8	2
1140	Principles of Surgery in Head and Neck Cutaneous Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 251-262.	0.4	1
1141	Imaging and Laboratory Workup for Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 235-250.	0.4	2



#	ARTICLE	IF	CITATIONS
1142	An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. <i>Annals of Surgical Oncology</i> , 2022, 29, 5221-5234.	0.7	15
1143	Validation of artificial intelligence prediction models for skin cancer diagnosis using dermoscopy images: the 2019 International Skin Imaging Collaboration Grand Challenge. <i>The Lancet Digital Health</i> , 2022, 4, e330-e339.	5.9	38
1144	Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study. <i>ESMO Open</i> , 2022, 7, 100469.	2.0	1
1158	Same-day or next-day sentinel node biopsy after lymphoscintigraphy for melanoma using Tc-labelled antimony sulphide colloid. <i>British Journal of Surgery</i> , 2020, 107, 1773-1779.	0.1	1
1160	Sentinel lymph node biopsy in patients with clinical stage IIB/C cutaneous melanoma: A national cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 754-760.	0.6	7
1161	Optimal systemic therapy for high-risk resectable melanoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 431-439.	12.5	12
1162	Sentinel Lymph Node Biopsy after Previous Radical Lymphadenectomy of the Same Lymph Node Basin. <i>Journal of Investigative Surgery</i> , 2022, 35, 1171-1175.	0.6	2
1163	Positive margins after surgical excision of locoregional cutaneous melanoma metastasis and their impact on patient outcome. <i>European Journal of Dermatology</i> , 2018, 28, 661-667.	0.3	3
1164	Patient Perception of the Diagnosis Announcement and its Impact on Quality of Life of Patients with Primary Melanoma or Basal Cell Carcinoma.. <i>Acta Dermato-Venereologica</i> , 2022, , .	0.6	1
1165	Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 615-617.	2.3	0
1166	Risk Stratification of Patients with Stage I Cutaneous Melanoma Using 31-Gene Expression Profiling.. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021, 14, E61-E63.	0.1	5
1167	Risk Factors and Predictors of Survival Among Patients with Amelanotic Melanoma Compared to Melanotic Melanoma in the National Cancer Database.. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021, 14, 36-43.	0.1	1
1170	Efficacy&nbsp;Comparison between Anti-PD-1 Antibody Monotherapy and Anti-PD-1 Plus Anti-CTLA-4 Combination Therapy as First-Line Immunotherapy for Advanced Acral Melanoma: A Retrospective, Multicenter Study of 254 Japanese Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1171	The Experience of 3D Total-Body Photography to Monitor Nevi: Results From an Australian General Population-Based Cohort Study. <i>JMIR Dermatology</i> , 2022, 5, e37034.	0.4	4
1173	Patient Perception of the Diagnosis Announcement and its Impact on Quality of Life of Patients with Primary Melanoma or Basal Cell Carcinoma. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00717.	0.6	3
1174	Chrysin enhances antitumour immunity response through the $\text{IL-12}\rightarrow\text{STAT4}$ signal pathway in the $\text{B16F10}$ melanoma mouse model. <i>Scandinavian Journal of Immunology</i> , 2022, 96, e13177.	1.3	6
1175	Extraordinarily aggressive cutaneous sarcomatoid squamous cell carcinoma of the face: a case report. <i>Archives of Craniofacial Surgery</i> , 2022, 23, 77-82.	0.4	2
1176	Development of an Image Analysis-Based Prognosis Score Using Googleâ€™s Teachable Machine in Melanoma. <i>Cancers</i> , 2022, 14, 2243.	1.7	7

#	ARTICLE	IF	CITATIONS
1177	Assessment of the Novel, Practical, and Prognosis-Relevant TNM Staging System for Stage I-III Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2022, 12, 738298.	1.3	1
1178	Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. <i>Science Translational Medicine</i> , 2022, 14, eabj9779.	5.8	18
1179	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5937-5945.	0.7	4
1180	Genome-Wide Association Study Suggests the Variant rs7551288*A within the DHCR24 Gene Is Associated with Poor Overall Survival in Melanoma Patients. <i>Cancers</i> , 2022, 14, 2410.	1.7	2
1181	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 236-255.	1.3	102
1182	Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma. <i>Cancers</i> , 2022, 14, 2294.	1.7	3
1183	Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 523-545.	3.3	2
1184	The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	18
1185	Introduction to Head and Neck Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 213-220.	0.4	1
1186	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 315-324.	0.4	2
1187	Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives. <i>Cancers</i> , 2022, 14, 2315.	1.7	7
1188	Future Treatments in Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 325-331.	0.4	1
1189	ASO Author Reflections: Why Treatment Risk Thresholds Are Needed for Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	1
1190	Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown. <i>Cancers</i> , 2022, 14, 2360.	1.7	10
1191	The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, 200.	1.8	0
1192	The future of targeted kinase inhibitors in melanoma. , 2022, 239, 108200.		17
1193	Melanoma lentiginoso acral ¿Qu¿ sabemos de uno de los melanomas mas frecuentes en Latinoam¿rica?. <i>Revista Colombiana De Cancerolog¿a</i> , 2021, 25, 140-53.	0.0	1
1194	Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	2

#	ARTICLE	IF	CITATIONS
1195	Factors Related to Delayed Diagnosis of Cutaneous Melanoma in the Brazilian Public Health System. <i>Journal of Cancer Education</i> , 2022, , .	0.6	0
1196	Disruption of Redox Homeostasis by Alterations in Nitric Oxide Synthase Activity and Tetrahydrobiopterin along with Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5979.	1.8	3
1197	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. <i>European Journal of Cancer</i> , 2022, 169, 210-222.	1.3	12
1198	Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 738-744.	1.8	5
1200	Sentinel node biopsy in thin melanoma: a retrospective descriptive cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	2
1201	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 256-284.	1.3	92
1202	CD3D Is an Independent Prognostic Factor and Correlates With Immune Infiltration in Gastric Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1203	The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (Nâ€‰=â€‰2,086). <i>BMC Cancer</i> , 2022, 22, .	1.1	5
1204	Evaluating and Embracing Modern Imaging Technology to Guide Sentinel Node Biopsy for Melanoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 5350-5352.	0.7	1
1205	Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies. <i>Modern Pathology</i> , 2022, 35, 1509-1514.	2.9	7
1206	Skin Cancer Disease Detection Using Transfer Learning Technique. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5714.	1.3	28
1207	Cutaneous melanoma. , 2023, , 370-375.		0
1210	Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. <i>Current Oncology Reports</i> , 2022, 24, 1273-1280.	1.8	5
1211	Does Residual Invasive Disease in Wide Local Excision after Diagnosis with Partial Biopsy Technique Influence Survival in Melanoma? Matched-Pair Analysis of Multicenter Selective Lymphadenectomy Trial I and II. <i>Journal of the American College of Surgeons</i> , 2022, 235, 49-59.	0.2	4
1212	Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00756.	0.6	8
1213	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	0.8	33
1214	A novel 7 RNA-based signature for prediction of prognosis and therapeutic responses of wild-type BRAF cutaneous melanoma. <i>Biological Procedures Online</i> , 2022, 24, .	1.4	0
1215	Advancedâ€‰Stage Melanoma at Presentation Following the Peak of the Pandemic: A COVIDâ€‰19 Cancer Canary in a Coal Mine. <i>World Journal of Surgery</i> , 2022, 46, 1820-1825.	0.8	5

#	ARTICLE	IF	CITATIONS
1216	Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage II Melanoma Patients at Risk of Disease Relapse. <i>Cancers</i> , 2022, 14, 2854.	1.7	9
1217	Sinonasal Mucosal Melanoma: Role of Tumor Proliferative Indices and Pathological Factors in Survival. <i>Laryngoscope</i> , 2022, 132, 2350-2358.	1.1	7
1218	Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group. <i>Clinical and Translational Oncology</i> , 2022, 24, 2010-2020.	1.2	8
1219	Symptomatic melanoma metastases in the brain: are we using all therapy options?. <i>Meditinskiy Sovet</i> , 2022, , 66-74.	0.1	0
1220	Immunophenotype of tumor-infiltrating lymphocytes in atypical Spitzoid tumors according to the risk of progression. <i>Annals of Diagnostic Pathology</i> , 2022, 60, 151985.	0.6	1
1221	Statistical analysis of 225 cases with malignant melanoma, assessed during 2008-2017, in the Department of Dermatology, Osaka City University Graduate School of Medicine. <i>Skin Cancer</i> , 2022, 37, 22-26.	0.1	0
1222	Primary Intracranial Brainstem Malignant Melanoma: A Technical Case Report. <i>Operative Neurosurgery</i> , 2022, 23, e139-e142.	0.4	1
1223	Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2022, 29, 7019-7028.	0.7	3
1224	Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration. <i>Annals of Surgical Oncology</i> , 2022, 29, 7010-7017.	0.7	3
1225	The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients. <i>Medicine and Pharmacy Reports</i> , 0, , .	0.2	1
1226	A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
1227	Role and Place of PET/CT in the Assessment of Skin Melanoma Prevalence. <i>Vestnik Rentgenologii i Radiologii</i> , 2022, 103, 77-82.	0.1	3
1228	A Novel Necroptosis-Related Gene Signature in Skin Cutaneous Melanoma Prognosis and Tumor Microenvironment. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	14
1229	Identification of a Seven-Differentially Expressed Gene-Based Recurrence-Free Survival Model for Melanoma Patients. <i>Disease Markers</i> , 2022, 2022, 1-14.	0.6	1
1230	Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlatedâ€”A Systematic Review. <i>BioMed Research International</i> , 2022, 2022, 1-12.	0.9	7
1231	Metastasis of Melanoma to the Adrenal Glands: A Case Report and Literature Review. <i>Cureus</i> , 2022, , .	0.2	1
1232	EPAC Regulates Melanoma Growth by Stimulating mTORC1 Signaling and Loss of EPAC Signaling Dependence Correlates with Melanoma Progression. <i>Molecular Cancer Research</i> , 2022, 20, 1548-1560.	1.5	3
1233	Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
1234	The Impact of SARS-CoV-2 Pandemic on Patients with Malignant Melanoma at a Romanian Academic Center: A Four-Year Retrospective Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8499.	1.2	8
1235	Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1312-1320.	0.6	12
1236	Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T <sub>reg</sub> reduction and effector T cell activation. <i>Science Immunology</i> , 2022, 7, .	5.6	18
1237	Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. <i>EBioMedicine</i> , 2022, 82, 104143.	2.7	12
1239	Follow-up Schedule for Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO) Trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1312-1320.	2.1	1
1240	Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	1
1241	Características del melanoma cutáneo en dos instituciones de Bogotá, Colombia: Análisis 2012-2016. <i>Revista Colombiana De Cancerología</i> , 2021, 25, 188-195.	0.0	2
1242	An updated algorithm integrated with patient data for the differentiation of atypical nevi from early melanomas: the idScore 2021. <i>Dermatology Practical and Conceptual</i> , 0, , e2022134.	0.5	5
1243	Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 3940-3951.	0.8	13
1244	Comparing the associations between host and tumor factors with survival outcomes with anti-PD-1 immunotherapy in metastatic melanoma. <i>Cancer Medicine</i> , 2023, 12, 2427-2439.	1.3	3
1245	Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1246	Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. <i>Quality of Life Research</i> , 0, , .	1.5	0
1247	Î±-Enolase inhibits apoptosis and promotes cell invasion and proliferation of skin cutaneous melanoma. <i>Molecular Biology Reports</i> , 2022, 49, 8241-8250.	1.0	2
1248	Dataset for the Reporting of Merkel Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 0, Publish Ahead of Print, .	2.1	1
1249	Acral Melanocytic Neoplasms: A Comprehensive Review of Acral Nevus and Acral Melanoma in Asian Perspective. <i>Dermatopathology (Basel, Switzerland)</i> , 2022, 9, 292-303.	0.7	5
1250	Investigation of CTLA4 <sup>TM</sup> s Application in Advanced Melanoma with Ipilimumab and Nivolumab. , 0, 8, 481-489.		0
1251	Prognostic or Therapeutic? The Role of Sentinel Lymph Node Biopsy in Contemporary Practice. <i>JAMA Surgery</i> , 2022, 157, 843.	2.2	3
1252	Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 599-615.	2.0	4

#	ARTICLE	IF	CITATIONS
1253	Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study. Pigment Cell and Melanoma Research, 2022, 35, 605-612.	1.5	8
1254	Efficacy of Large Use of Combined Hypofractionated Radiotherapy in a Cohort of Anti-PD-1 Monotherapy-Treated Melanoma Patients. Cancers, 2022, 14, 4069.	1.7	4
1255	Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study. , 2022, 10, e005226.		17
1256	Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed?. Lancet, The, 2022, 400, 559.	6.3	1
1257	Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European Journal of Cancer, 2022, 173, 285-296.	1.3	16
1258	Reporting of melanoma cell densities in the sentinel node refines outcome prediction. European Journal of Cancer, 2022, 174, 121-130.	1.3	2
1259	Four Immune Modulating Genes in Primary Melanoma That Predict Metastatic Potential. Journal of Surgical Research, 2022, 279, 682-691.	0.8	1
1260	A general class of promotion time cure rate models with a new biological interpretation. Lifetime Data Analysis, 2023, 29, 66-86.	0.4	1
1261	Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy. Acta OncolÃ³gica, 2022, 61, 1116-1120.	0.8	2
1262	Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages Iâ€“III. European Journal of Cancer, 2022, 175, 196-203.	1.3	1
1263	Anti-melanoma effect and action mechanism of a novel chitosan-based composite hydrogel containing hydroxyapatite nanoparticles. International Journal of Energy Production and Management, 2022, 9, .	1.9	2
1264	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2022, , 1235-1269.		0
1265	Radioguided Surgery for Malignant Melanoma. , 2022, , 1595-1631.		0
1266	Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapies. Postepy Dermatologii I Alergologii, 2022, 39, 1141-1150.	0.4	1
1267	Clinicopathologic characteristics of cutaneous melanoma - A single-center retrospective study. Srpski Arhiv Za Celokupno Lekarstvo, 2022, 150, 533-538.	0.1	0
1268	Contrastive and Attention-Based Multiple Instance Learning for the Prediction of Sentinel Lymph Node Status from Histopathologies of Primary Melanoma Tumours. Lecture Notes in Computer Science, 2022, , 57-66.	1.0	0
1269	Health-related quality of life in stage IIIâ€“IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials. Cancer Medicine, 2023, 12, 2262-2280.	1.3	1
1270	Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 15, 1743-1757.	0.8	4



#	ARTICLE	IF	CITATIONS
1271	Resilience of melanoma diagnostics at a tertiary-care hospital during the SARS-CoV-2 pandemic. <i>JAAD International</i> , 2022, 9, 78-79.	1.1	0
1272	Multivariate logistic regression analysis of the correlation between five biomarkers and ovarian cancer in patients with intermediate-risk: A prospective cross-sectional study. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
1273	Evaluation of the Transplant Recipient. <i>Nephrology Self-assessment Program: NephSAP</i> , 2022, 21, 246-258.	3.0	0
1274	<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	5
1275	WZB117 enhanced the anti-tumor effect of apatinib against melanoma via blocking STAT3/PKM2 axis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1276	Hypoxia and Ezrin Expression in Primary Melanoma Have High Prognostic Relevance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10745.	1.8	1
1277	Detection of cutaneous malignant melanoma using RNA sampled by tape strips: A study protocol. <i>PLoS ONE</i> , 2022, 17, e0274413.	1.1	4
1278	Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1279	Transcriptome profiles of fatty acid metabolism-related genes and immune infiltrates identify hot tumors for immunotherapy in cutaneous melanoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1280	Neoadjuvant therapy for melanoma: A critical appraisal. <i>Journal of Surgical Oncology</i> , 0, , .	0.8	0
1281	HLA-DRB1: A new potential prognostic factor and therapeutic target of cutaneous melanoma and an indicator of tumor microenvironment remodeling. <i>PLoS ONE</i> , 2022, 17, e0274897.	1.1	3
1282	Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	0.6	3
1283	Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma. <i>Cancer</i> , 2022, 128, 3764-3771.	2.0	1
1284	Clinical predictors of survival in real world practice in stage IV melanoma. <i>Cancer Reports</i> , 0, , .	0.6	1
1285	Melanoma Management: From Epidemiology to Treatment and Latest Advances. <i>Cancers</i> , 2022, 14, 4652.	1.7	32
1286	Identification of a predictive gene signature related to pyroptosis for the prognosis of cutaneous melanoma. <i>Medicine (United States)</i> , 2022, 101, e30564.	0.4	2
1287	Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. , 2022, 1, .		29
1288	Comprehensive transcriptomic analysis of immune-related eRNAs associated with prognosis and immune microenvironment in melanoma. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0



#	ARTICLE	IF	CITATIONS
1289	Identification of an endoplasmic reticulum stress-associated gene signature to predict the immune status and prognosis of cutaneous melanoma. <i>Medicine (United States)</i> , 2022, 101, e30280.	0.4	0
1290	Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
1292	Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 52-59.	0.6	8
1293	DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness. <i>ELife</i> , 0, 11, .	2.8	2
1294	Ulceration vs. Mitosis in Cutaneous Melanoma: Which Is Superior for Predicting Prognosis Across Clinical Stages?. <i>Cancer Investigation</i> , 2022, 40, 842-851.	0.6	0
1295	Pigmented Nail Lesions: When to Observe, When to Biopsy, When to Widely Excise, and When to Amputate?. <i>Journal of Hand Surgery</i> , 2022, 47, 988-997.	0.7	2
1296	Causes, consequences and clinical significance of aneuploidy across melanoma subtypes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1297	Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. <i>European Journal of Cancer</i> , 2022, 176, 207-217.	1.3	7
1298	Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework. <i>Implementation Science Communications</i> , 2022, 3, .	0.8	1
1299	Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients. <i>European Journal of Cancer</i> , 2022, 176, 78-87.	1.3	13
1301	Systemic adjuvant therapy for high-risk cutaneous melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211340.	1.4	7
1302	Advances in the Application of Nanomaterials to the Treatment of Melanoma. <i>Pharmaceutics</i> , 2022, 14, 2090.	2.0	2
1303	Effects of modern antitumor drug therapy possibilities to skin melanoma on oncological and epidemiological indicators in the Krasnoyarsk region. <i>Russian Journal of Oncology</i> , 2022, 26, 111-120.	0.1	0
1304	The importance of mitosis $\hat{\alpha}\%¥2$ in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy. <i>Melanoma Research</i> , 2022, 32, 469-476.	0.6	0
1306	Comparison of 18F-FDG PET/CT and ultrasound in staging of patients with malignant melanoma. <i>Medicine (United States)</i> , 2022, 101, e31092.	0.4	0
1307	Hyperspectral Imaging for Non-invasive Diagnostics of Melanocytic Lesions. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00815.	0.6	1
1309	Prediction of early-stage melanoma recurrence using clinical and histopathologic features. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	10
1310	Machine Learning Techniques in Predicting BRAF Mutation Status in Cutaneous Melanoma From Clinical and Histopathologic Features. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 674-680.	0.6	3

#	ARTICLE	IF	CITATIONS
1311	Melanoma lymph node metastases â€œ moving beyond quantity in clinical trial design and contemporary practice. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1313	Nerve Density and Neuronal Biomarkers in Cancer. <i>Cancers</i> , 2022, 14, 4817.	1.7	11
1314	Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma. <i>Cancers</i> , 2022, 14, 4973.	1.7	1
1315	Identification of an ergosterol derivative with anti-melanoma effect from the sponge-derived fungus <i>Pestalotiopsis</i> sp. XWS03F09. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
1316	Obstructive sleep apnoea is related to melanoma aggressiveness through paraspeckle protein-1 upregulation. <i>European Respiratory Journal</i> , 2023, 61, 2200707.	3.1	6
1317	Melanoma classification and management in the era of molecular medicine. <i>Dermatologic Clinics</i> , 2023, 41, 49-63.	1.0	15
1318	Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. <i>JAMA Oncology</i> , 2022, 8, 1794.	3.4	33
1319	Vulvar Malignant Melanoma: A Narrative Review. <i>Cancers</i> , 2022, 14, 5217.	1.7	2
1321	Neoadjuvant relatlimab and nivolumab in resectable melanoma. <i>Nature</i> , 2022, 611, 155-160.	13.7	114
1322	A population-based cohort study for presence of ulceration among cutaneous malignant melanoma subgroups of patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1323	Near complete remission of a locally advanced giant melanoma of the vulva following hypoâ€œfractionated radiotherapy and immune checkpoint inhibitors: A case report. <i>Oncology Letters</i> , 2022, 24, .	0.8	1
1324	Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1378-1388.	5.1	64
1325	Prognostic significance of age on superficial spreading melanoma after resection: lessons from <sc>SEER</sc> database involving 12â€œ536 patients. <i>ANZ Journal of Surgery</i> , 0, , .	0.3	0
1326	Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics. <i>Future Oncology</i> , 2022, 18, 3755-3767.	1.1	1
1327	Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with veryâ€œlow melanoma mortality. <i>Cancer</i> , 2023, 129, 89-97.	2.0	7
1328	Recurrence of a Cellular Blue Nevus with Satellitosisâ€œA Diagnostic Pitfall with Clinical Consequences. <i>Dermatopathology (Basel, Switzerland)</i> , 2022, 9, 361-367.	0.7	0
1329	Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1330	Subcapsular Sinus Macrophages Promote Melanoma Metastasis to the Sentinel Lymph Nodes via an IL1Î±â€œSTAT3 Axis. <i>Cancer Immunology Research</i> , 2022, 10, 1525-1541.	1.6	3

#	ARTICLE	IF	CITATIONS
1331	Sentinel Lymph Node Biopsy in Cutaneous Melanoma, a Clinical Point of View. <i>Medicina (Lithuania)</i> , 2022, 58, 1589.	0.8	1
1332	Genomic and proteomic findings in early melanoma and opportunities for early diagnosis. <i>Experimental Dermatology</i> , 2023, 32, 104-116.	1.4	1
1333	The Integrated 31-Gene Expression Profile (i31-GEP) Test for Cutaneous Melanoma Outperforms a Clinicopathologic-only Nomogram at Identifying Patients who can Forego Sentinel Lymph Node Biopsy. <i>SKIN the Journal of Cutaneous Medicine</i> , 2022, 6, 463-473.	0.1	4
1334	The Integrated 31-Gene Expression Profile Test (i31-GEP) for Cutaneous Melanoma Outperforms the CP-GEP at Identifying Patients who can Forego Sentinel Lymph Node Biopsy when Applying NCCN Guidelines. <i>SKIN the Journal of Cutaneous Medicine</i> , 2022, 6, 474-481.	0.1	1
1335	Identification of m7G-associated lncRNA prognostic signature for predicting the immune status in cutaneous melanoma. <i>Aging</i> , 2022, 14, 5233-5249.	1.4	19
1336	Classifications. , 2022, , 13-24.		0
1337	Ultrasound of Cutaneous Melanoma: Primary Tumor Assessment and Locoregional Staging. , 2022, , 213-249.		1
1338	Patient Preferences and Satisfaction With Decisions in Stage-III Melanoma: A Mixed Methods Study. <i>Journal of Surgical Research</i> , 2023, 283, 485-493.	0.8	0
1339	Integration of Context. , 2022, , 79-99.		0
1340	Dermatologic Concepts and Terminology. , 2022, , 21-72.		0
1341	Amelanotic nodular malignant melanoma in a patient with a family history of skin cancers. <i>Russian Journal of Skin and Venereal Diseases</i> , 2022, 25, 261-268.	0.0	0
1342	Not Your Mother's Melanoma: Causes and Effects of Early Melanoma Diagnosis. <i>Dermatopathology (Basel, Switzerland)</i> , 2022, 9, 368-378.	0.7	0
1343	Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	2
1344	Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis. <i>International Journal of Dermatology</i> , 2023, 62, 56-61.	0.5	1
1345	Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. <i>Cancers</i> , 2022, 14, 5676.	1.7	3
1346	Melanoma awareness and prevention among latinx and non-latinx white adults in urban and rural California: A qualitative exploration. <i>Cancer Medicine</i> , 2023, 12, 7438-7449.	1.3	4
1347	Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysis. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 802-807.	0.6	6
1348	Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune checkpoint inhibitors in Australian tertiary oncology centres. <i>Cancer Medicine</i> , 2023, 12, 6788-6801.	1.3	2

#	ARTICLE	IF	CITATIONS
1349	Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 5789.	1.7	3
1350	PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1351	Risk of Overusing Sentinel Node Biopsy in Patients With Thin Melanoma. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
1352	Reply to A. Mangla and E. Hindi. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
1353	Molecular Detection of Lymph Node Metastases in Lung Cancer Patients Using the One-Step Nucleic Acid Amplification Method: Clinical Significance and Prognostic Value. <i>Cells</i> , 2022, 11, 4010.	1.8	0
1354	Metastatic melanoma and rare melanoma variants: a review. <i>Pathology</i> , 2023, 55, 236-244.	0.3	6
1355	<scp>FLI</scp> / <scp>Melanâ€A</scp> dual stain is an alternative to <scp>PRAME</scp> in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study. <i>Journal of Cutaneous Pathology</i> , 0, , .	0.7	2
1356	Impact of the COVID-19 Pandemic on Melanoma Diagnosis: Increased Breslow Thickness in Primary Melanomasâ€”A Single Center Experience. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16806.	1.2	5
1357	ASO Author Reflections: Risk Stratification of Sentinel Node Metastases in Stage III Melanoma Patients in the Era of Adjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
1358	Melanoma of the Scalp and Neck: A Population-Based Analysis of Survival and Treatment Patterns. <i>Cancers</i> , 2022, 14, 6052.	1.7	1
1359	The number of metastatic lymph nodes optimizes staging in patients aged 55 years or older with papillary thyroid cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
1360	Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. <i>Neuro-Oncology</i> , 2023, 25, 1310-1320.	0.6	5
1361	Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy. <i>Melanoma Research</i> , 2023, 33, 84-86.	0.6	0
1362	The expression pattern of pyroptosis-related genes predicts the prognosis and drug response of melanoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1363	Serum Neu5Gc biomarkers are elevated in primary cutaneous melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2023, 642, 162-166.	1.0	3
1364	The Utility of Pre-Treatment Inflammation Markers as Associative Factors to the Adverse Outcomes of Vulvar Cancer: A Study on Staging, Nodal Involvement, and Metastasis Models. <i>Journal of Clinical Medicine</i> , 2023, 12, 96.	1.0	2
1365	Evaluation of dynamic dermoscopic features of melanoma and benign naevi by sequential digital dermoscopic imaging and total body photography in a highâ€risk Australian cohort. <i>Australasian Journal of Dermatology</i> , 0, , .	0.4	1
1366	Melanoma Survival by Age Group: Population-Based Disparities for Adolescent and Young Adult Patients by Stage, Tumor Thickness, and Insurance Type. <i>Journal of the American Academy of Dermatology</i> , 2023, , .	0.6	0

#	ARTICLE	IF	CITATIONS
1367	Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis. <i>Cancers</i> , 2023, 15, 409.	1.7	3
1368	Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage Iâ€“IIA cutaneous melanoma. <i>European Journal of Cancer</i> , 2023, 182, 77-86.	1.3	5
1369	Phytochemical Constituents and Derivatives of Cannabis sativa; Bridging the Gap in Melanoma Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 859.	1.8	8
1370	Real-world treatment patterns and outcomes in patients with metastatic melanoma. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2023, , 6-6.	0.1	0
1371	Construction, validation and, visualization of a web-based nomogram to identify the best candidates for primary tumor resection in advanced cutaneous melanoma patients. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
1372	Conditional survival in patients with stage IBâ€“IIA melanoma undergoing sentinel node biopsy in Queensland: A longitudinal study. <i>Australasian Journal of Dermatology</i> , 0, , .	0.4	0
1373	Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas. <i>Oncolmmunology</i> , 2023, 12, .	2.1	4
1374	Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1375	Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma â€“ Authors' reply. <i>Lancet Oncology</i> , The, 2023, 24, e8.	5.1	0
1376	Outcomes of invasive melanoma of the head and neck treated with Mohs micrographic surgery â€“ A multicenter study. <i>Journal of the American Academy of Dermatology</i> , 2023, 89, 544-550.	0.6	5
1377	Association of metformin use and survival in patients with cutaneous melanoma and diabetes. <i>British Journal of Dermatology</i> , 2023, 188, 32-40.	1.4	4
1378	Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). <i>European Journal of Cancer</i> , 2023, 182, 155-162.	1.3	9
1379	Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases. <i>Cancers</i> , 2023, 15, 161.	1.7	1
1380	Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. <i>European Journal of Cancer</i> , 2023, 182, 163-169.	1.3	6
1381	Establishment and validation of a nomogram for predicting immune-related prognostic features in trunk melanoma-specific death. <i>Annals of Translational Medicine</i> , 2022, 10, 1371-1371.	0.7	0
1382	Melanoma in pregnancy. <i>Abdominal Radiology</i> , 2023, 48, 1740-1751.	1.0	1
1383	C-Reactive Protein and Lymphocyte-to-Monocyte Ratio Predict Recurrence in Stage III Melanoma Patients with Microscopic Sentinel Lymph Node Metastasis. <i>Cancers</i> , 2023, 15, 702.	1.7	1
1384	Tumor immunology. , 2023, , 245-452.		0

#	ARTICLE	IF	CITATIONS
1385	A role for pelvic sentinel lymph nodes in lower extremity melanoma?. <i>Scandinavian Journal of Surgery</i> , 0, , 145749692211499.	1.3	0
1386	The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study. <i>Current Medical Research and Opinion</i> , 2023, 39, 417-423.	0.9	3
1387	Skin cancer excisions and histopathology outcomes when following a contemporary populationâ€based cohort longitudinally with 3D totalâ€body photography. <i>Skin Health and Disease</i> , 2023, 3, .	0.7	1
1388	Conventional and three-dimensional photography as a tool to map distribution patterns of in-transit melanoma metastases on the lower extremity. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
1389	KutanÃ–z Malign Melanom Nedeniyle Takip EttiÃ–yimiz HastalarÃ–n Klinikopatolojik Ã–zellikleri. <i>Turkish Journal of Clinics and Laboratory</i> , 0, , .	0.2	0
1390	Lyotropic Liquid Crystal Precursor as an Innovative Herpes Simplex Virus Vector for Melanoma Therapy. , 0, , .		0
1391	The Evolution of the Sentinel Node Biopsy in Melanoma. <i>Life</i> , 2023, 13, 489.	1.1	1
1392	Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4302.	1.8	0
1393	Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report. , 2023, 11, e006467.		1
1394	The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. <i>Nature Communications</i> , 2023, 14, .	5.8	17
1395	Checkpoint blockade and <scp>BRAF</scp>/<scp>MEK</scp> therapy in the therapeutic setting improved the overall survival after sentinel node biopsy: A retrospective study comparing patients with primary care between 1998â€2009 and 2010â€2017. <i>International Journal of Cancer</i> , 2023, 153, 380-388.	2.3	0
1396	Immune infiltration associated C1q acts as a novel prognostic biomarker of cutaneous melanoma. <i>Medicine (United States)</i> , 2023, 102, e33088.	0.4	0
1397	Dermoscopic features associated with 3â€GEP PLA: LINC00518, PRAME, and TERT expression in suspicious pigmented lesions. <i>Skin Research and Technology</i> , 2023, 29, .	0.8	3
1398	Adherence with surveillance schedule in patients with invasive melanoma. <i>Surgical Oncology</i> , 2023, 48, 101943.	0.8	0
1399	Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies. <i>European Journal of Cancer</i> , 2023, 186, 27-37.	1.3	1
1400	No association between physical activity and primary melanoma thickness in a cohort of Norwegian women. <i>British Journal of Dermatology</i> , 2023, 188, 670-690.	1.4	0
1401	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
1402	A Rapidly Changing Skin Lesion in an 11-year-old Boy. <i>Pediatrics in Review</i> , 2023, 44, 96-99.	0.2	1

#	ARTICLE	IF	CITATIONS
1403	Immunotherapy for Cutaneous Melanoma. , 2023, , 1-35.		0
1404	Reducing workload in malignant melanoma sentinel node examination: a national study of pathology reports from 507 melanoma patients. <i>Journal of Clinical Pathology</i> , 0, , jcp-2022-208743.	1.0	0
1405	Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients. <i>Annals of Surgical Oncology</i> , 2023, 30, 2377-2388.	0.7	2
1406	Nanodelivery systems for cutaneous melanoma treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2023, 184, 214-247.	2.0	6
1407	Long-Term Sequential Digital Dermoscopy of Low-Risk Patients May Not Improve Early Diagnosis of Melanoma Compared to Periodical Handheld Dermoscopy. <i>Cancers</i> , 2023, 15, 1129.	1.7	0
1408	Revisiting the Role of the CXCL13/CXCR5-Associated Immune Axis in Melanoma: Potential Implications for Anti-PD-1-Related Biomarker Research. <i>Life</i> , 2023, 13, 553.	1.1	2
1409	Impact of second histopathological review of melanocytic skin lesions at a melanoma reference center in Brazil. <i>Italian Journal of Dermatology and Venereology</i> , 2023, 158, .	0.1	0
1410	Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. <i>Cancers</i> , 2023, 15, 1404.	1.7	0
1411	BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2022, 10, e4605.	0.3	1
1412	The effect of tumor mitotic rate on melanoma-specific survival: An analysis of 54,598 cases. <i>Journal of the American Academy of Dermatology</i> , 2023, , .	0.6	0
1413	Long-term outcomes of margin-controlled excision for eyelid melanoma. <i>Eye</i> , 2023, 37, 1009-1013.	1.1	1
1414	Adjuvant treatment of inâ€transit melanoma: Narrowing the knowledge gap left by clinical trials. <i>International Journal of Cancer</i> , 0, , .	2.3	0
1415	Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy. <i>Cells</i> , 2023, 12, 789.	1.8	2
1416	The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography. <i>Melanoma Research</i> , 2023, 33, 199-207.	0.6	0
1417	Early inflammatory biomarkers and melanoma survival. <i>International Journal of Dermatology</i> , 0, , .	0.5	3
1418	The Importance of Immunohistochemistry in the Evaluation of Tumor Depth of Primary Cutaneous Melanoma. <i>Diagnostics</i> , 2023, 13, 1020.	1.3	2
1420	Cutaneous Melanoma and Glioblastoma Multiforme Associationâ€”Case Presentation and Literature Review. <i>Diagnostics</i> , 2023, 13, 1046.	1.3	0
1421	Melanoma of unknown primary origin with skeletal muscle metastasis: a case report. <i>Journal of Medical Case Reports</i> , 2023, 17, .	0.4	0



#	ARTICLE	IF	CITATIONS
1422	Similar local recurrence and survival in patients with <scp>T1</scp> radial growth phase melanoma on head and neck treated with 5 or 10â€‰%mm margins: A retrospective study. Journal of the European Academy of Dermatology and Venereology, 2023, 37, 1318-1326.	1.3	0
1423	Trends and patterns of care of sentinel node biopsy in cutaneous melanoma: a <scp>populationâ€based</scp> study in <scp>Queensland</scp>. ANZ Journal of Surgery, 0, , .	0.3	2
1424	Oncological healthcare providersâ€™ perspectives on appropriate melanoma survivorship care: a qualitative focus group study. BMC Cancer, 2023, 23, .	1.1	1
1425	Long-term outcomes of stage IIBâ€“IV melanoma patients: nationwide data from Norway. Future Oncology, 2023, 19, 205-215.	1.1	0
1426	Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of Melanoma in ultra-hiGh and high-risk patiEnts (the Tj ETQq0 0 0 rg07/Overlozk 10 Tf 50		
1427	Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study. Melanoma Research, 2023, 33, 388-397.	0.6	2
1428	Melanoma of eyelid and periocular skin. , 2023, , 245-251.		0
1429	InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PLoS ONE, 2023, 18, e0269324.	1.1	3
1430	Opportunities to inform German residents about the possibility of skin cancer screening and to inform stakeholders to take appropriate actions: A qualitative approach. Cancer Medicine, 0, , .	1.3	1
1453	Emerging Soft Computation Tools for Skin Cancer Diagnostics. EAI/Springer Innovations in Communication and Computing, 2023, , 265-283.	0.9	0
1502	Oncolytic intralesional therapy for metastatic melanoma. Clinical and Experimental Metastasis, 0, , .	1.7	0
1545	Sentinel Lymph Node Biopsy. , 2023, , 1455-1460.		0
1546	Vulvar Diseases. , 2023, , 1091-1111.		0
1556	Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. Clinical and Experimental Metastasis, 0, , .	1.7	1
1562	Automatic Detection of Melanoma in Human Skin Lesions. Communications in Computer and Information Science, 2023, , 220-234.	0.4	0
1581	Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance?. Clinical and Experimental Metastasis, 0, , .	1.7	0
1601	Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment. Clinical and Experimental Metastasis, 0, , .	1.7	0
1616	Prognostic Factors, Staging, and Reporting of Melanoma. , 2024, , 261-268.		0

#	ARTICLE	IF	CITATIONS
1617	Melanoma Metastatic to the Skin. , 2024, , 251-260.		0